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Hemes are metalloporphyrins used by nearly all organisms as cofactors for proteins 
involved in respiration, binding and sensing gases, and as catalysts for various 
reactions. Despite extensive knowledge about heme biosynthesis and catabolism, the 
pathways for transporting heme between cells and within cells remain poorly 
understood. C. elegans serves as a unique animal model for uncovering these 
pathways, as it is unable to synthesize its own heme and depends on the uptake of 
dietary heme for growth and reproduction. Functional RNAi screens implicated mrp-
5 as a potential heme transporter in C. elegans. This gene encodes a membrane-bound 
ABC transporter that localizes to the basolateral intestinal membrane and is required 
for worm growth and reproduction. Depletion of mrp-5 activates heme deprivation 
signals within the worm, protects worms from toxicity associated with a toxic heme 
analog, and results in worms accumulating the fluorescent heme analog, zinc 
mesoporphyrin IX, in intestinal cells. Taken together, these results indicate a defect in 
  
heme export from the intestine when MRP-5 activity is lost. Functional assays in 
yeast support the hypothesis that MRP-5 is capable of exporting heme across cell 
membranes, and that this function is conserved in the human ortholog. Knockdown of 
mrp5 in zebrafish embryos results in developmental defects and decreased blood 
formation, indicating that this transporter likely regulates heme homeostasis in 
vertebrates. Loss of Mrp5 in mammalian cells leads to decreased heme transport into 
the secretory pathway as measured by activity of a Golgi-targeted heme-dependent 
enzyme. Furthermore, macrophages from mice lacking Mrp5 are unable to activate a 
number of cellular responses when undergoing erythrophagocytosis, the process 
whereby the heme-iron in senescent red bloods is recycled. Altogether, our results 
implicate MRP-5 as a key heme transporter in C. elegans, and point to an 
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Heme is an iron-containing porphyrin that functions as a cofactor in a huge 
array of cellular processes. Heme is also a major source of bioavailable iron in the 
human diet. By the end of the 20
th
 century, the pathways for heme biosynthesis had 
been well elucidated and the structures of many heme-containing proteins have been 
solved. Indeed, Max Perutz and John Kendrew were awarded the Nobel Prize in 
chemistry in 1962 for their crystal structures of hemoglobin and myoglobin (1, 2). 
While the synthesis of heme has been well-characterized, the pathways for inter- and 
intra-cellular heme transport remain poorly understood. This gap in our knowledge is 
largely due to the inability to uncouple the processes of heme biosynthesis and heme 
transport, as well as the ability of heme to promiscuously bind to proteins. Progress in 
this field can be contrasted with the fields of iron and copper trafficking, which have 
not suffered similar setbacks and have progressed steadily over the past decade. 
The Biological Requirement for Heme Trafficking Molecules 
 The terminal step of heme biosynthesis, which occurs in the mitochondrial 
matrix, is the insertion of iron into protoporphyrin IX. Heme is then targeted to both 
soluble and membrane-bound hemoproteins. Heme must be able to cross membranes, 
yet also be delivered to soluble proteins in the cytosol. Heme’s amphipathic nature 




protein partners. Due to the hydrophobicity of the porphyrin ring, heme is not readily 
soluble in aqueous solutions. When heme is at neutral pH and is in the ferrous state it 
has no net charge, as the negative charges of the propionate groups balance the 
positive charges of the chelated iron. While this form of heme readily inserts into and 
diffuses through lipid bilayers, the hydrophilic propionate head groups hinder the 
flipping of heme from one leaflet to another (3-5). Heme exit from the membrane is 
inefficient without the presence of soluble heme binding proteins (6).  
In addition to the difficulties posed by heme’s dual chemical nature, its 
peroxidase activity and capacity to generate reactive oxygen species combined with 
its ability to intercalate into membranes and bind many proteins nonspecifically 
renders heme highly toxic. The deleterious effects of heme have been reviewed 
extensively in mammalian cells and other systems (7-12). Thus, even though heme is 
able to diffuse into membranes and be extracted by heme-binding proteins, it is 
unlikely that this process would be unregulated, as peroxidation of membrane lipids 
would result in severe damage, especially during a process such as erythropoiesis, 
with each red cell processing the heme required for over 300 million hemoglobin 
molecules. Additionally, many heme synthesis precursors and heme breakdown 
products are also toxic, and thus careful control of heme synthesis, trafficking, and 
degradation is a prerequisite.  
Given these chemical and biochemical properties of heme, it is apparent that a 
system of transporters and chaperones would be necessary to efficiently and 
specifically distribute heme to hemoproteins found in various compartments in the 




Delivery of Heme to Subcellular Compartments 
Heme Requirements in the Mitochondria 
 
  Most of the mitochondrial respiratory chain complexes rely on the redox 
capability of a heme prosthetic group (Table 1). Heme is present in these complexes 
in the a, b, or c forms. Heme b is the most common form of heme. It is the form 
synthesized by ferrochelatase, containing a C2 vinyl group and C8 methyl group, and 
is attached to proteins via noncovalent coordination of the heme iron with amino acid 
side chains (13, 14). Heme a is modified from heme b and its porphyrin ring contains 
a C2 hydroxyethylfarnesyl and a C8 formyl side group (14). Heme c is found 
covalently linked to proteins; the two vinyl side chains are converted to thioether 
linkages to cysteine residues in the apoprotein (15). 
The biogenesis and cofactor requirements of the mitochondrial respiratory 
complexes have recently been reviewed, but will be briefly discussed here with 
regard to heme transport and trafficking (16-18). The cytochrome bc1 complex (also 
known as coenzyme Q-cytochrome c reductase or Complex III) is a multi-subunit 
protein located with the other electron transport complexes in the inner mitochondrial 
membrane (IMM). The cytochrome bc1 complex includes two heme b-containing 
cytochromes as well as a heme c-containing cytochrome, and interacts with another 
hemoprotein, the electron carrier cytochrome c, for the purpose of generating a proton 
gradient along the IMM. Cytochrome c is soluble in the intermembrane space (IMS) 
of mitochondria and is found loosely associated with the IMM, as it carries an 
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oxidase (also known as Complex IV) includes two heme a-containing cytochromes, 
which also participate in electron transfer and proton translocation into the IMS. 
Succinate dehyrogenase (Complex II) also contains a heme b moiety, which is 
required for stability of the complex (19). The heme b in succinate dehydrogenase 
may also be involved in electron transport, but the exact function of this heme 
remains unclear (16). 
In eukaryotes, the cytochrome bc1 complex (Complex III) is composed of seven or 
eight nuclear-encoded subunits that function together with three catalytic core 
proteins encoded in the mitochondrial genome (20-22). Cytochrome b is a membrane-
bound core protein that contains two heme groups, each of which has a unique redox 
potential (23). Heme bH, the high potential heme, is bound in an accessible cavity on 
the matrix side of the protein. Heme bL, the low potential heme, is found within the 
IMS portion of cytochrome b. Heme bH can be inserted into cytochrome b without 
having to traverse a membrane; it is unknown whether or not a chaperone assists in 
this process (24). It is unclear if heme bL is acquired in the matrix, or if this heme is 
inserted in the IMS, thus necessitating movement of heme across the IMM (Figure 1, 
Pathway 1). Cytochrome c1, being nuclear encoded, is targeted to the mitochondria 
after being translated in the cytosol. Its heme cofactor is covalently attached in the 
IMS by the heme lyases Cyc3 and Cyt2 in yeast or holocytochrome c synthase 
(HCCS) in mammals (25). In addition to the heme in cytochrome c1 and possibly the 
heme bH of cytochrome b, the soluble respiratory protein cytochrome c also acquires 






Figure 1.1: Presumptive pathways for delivery of heme to hemoproteins in 
eukaryotic cells.  
Pathways are numbered as follows: 1) Heme transport across the inner mitochondrial 
membrane, 2) Heme transport across the outer mitochondrial membrane, 3) Direct 
heme trafficking from the mitochondria to the ER via mitochondria-associated 
membranes (MAMs), 4) Trafficking of heme from mitochondria to endolysosomal 
compartments via mitochondrial-derived vesicles (MDVs), 5) Transport of cytosolic 
heme into the secretory pathway by a heme exporter, 6) Trafficking of heme in 
ER/Golgi to endolysosomal compartments, 7) Import of heme into the cell via an 




 The biogenesis of cytochrome c oxidase (Complex IV) is highly conserved in 
eukaryotes (18). Heme a in cytochrome c oxidase (COX) is bound to the 
mitochondrial-encoded COX1 subunit. Heme a is synthesized via the conversion of 
heme b to the intermediate heme o by the farnesylation of the C2 position by COX10 
(heme o synthase), and the subsequent oxidation of the C2 methyl side chain to 
formyl by COX15 (heme a synthase) (14, 18). Both COX10 and COX15 are integral 
membrane proteins located in the IMM. Studies have indicated that insertion of heme 
a into COX1 occurs post-translationally, as early intermediates of the cytochrome c 
oxidase assembly do not contain heme a and are able to form in the absence of heme 
a biosynthesis (26). This is in contrast with later intermediates, which do not form 
without the presence of heme a. It remains unclear if heme chaperones exist to shuttle 
heme b from its site of synthesis to COX10, or to deliver heme a to the COX1 
subunit. By contrast, multiple mitochondrial chaperones, including COX17, SCO1, 
and COX11, have been shown to act as chaperones for delivery of copper to the 
cytochrome c oxidase complex [Also reviewed in (18)]. 
 In addition to the respiratory chain complex proteins, another cytochrome, 
cytochrome P450 side-chain cleavage enzyme (also known as CYP11A1), is also 
found in the mitochondrial matrix. This enzyme is expressed in steroid-synthesizing 
tissues such as the brain and adrenal glands and functions to convert cholesterol to 
pregnenolone, a precursor for mineralocorticoids, glucocorticoids, androgens, and 
estrogens (27). CYP11A1 catalyzes this first step in steroid synthesis by initiating 
three sequential monooxygenase reactions of the cholesterol side chain: 




steroid precursor pregnenolone and isocaproic aldehyde. While the crystal structures 
of both bovine and human CYP11A1 have recently been solved, nothing is known 
regarding how the heme cofactor is inserted into this important hemoprotein (28, 29). 
Heme Requirements in the Cytosol 
While heme moves from the mitochondrial matrix into the IMS for insertion 
into particular cytochromes, heme must also exit the mitochondria for insertion into 
hemoproteins which acquire heme in the cytosol (Table 1). The most well-known 
cytosolic hemoproteins are the gas-binding globins, including hemoglobin, 
myoglobin, neuroglobin, and cytoglobin. Adult hemoglobin consists of two α and two 
β chains, each bound to a molecule of heme. Hemoglobin can be generated in vitro 
(for example, by heterologous expression in E. coli, or by recombining purified apo-
hemoglobin with heme) indicating that no specific chaperone is required for heme 
insertion. Because of its asymmetric side chains, each heme can be incorporated into 
hemoglobin in two orientations. The term “heme disorder” refers to mixtures of these 
two orientations within a subset of hemoglobin molecules (30). Interestingly, the 
amount of heme disorder differs between hemoglobin synthesized in vivo or in vitro 
(31). This is a possible indication that stereoselective insertion of heme into 
hemoglobin occurs, although the mechanism for this phenomenon remains unclear. 
Other hemoproteins that must acquire their heme in cytosol include nitric 
oxide synthases and the soluble guanylyl cyclases (a nitric oxide receptor), nuclear 
heme-binding proteins including Hap1p, DGCR8, mPer2, Bach1 and Rev-erb-α, as 
well as the soluble form of cytochrome b5. Even P450 cytochromes, the most well-




containing globular domain facing the cytosol (32, 33). Thus, cytochrome P450 
proteins may acquire their heme from the cytosolic face of the membrane. 
Heme Delivery to Cytosolic Proteins 
Cytosolic hemoproteins can acquire their heme from two possible sources: 
heme synthesized de novo in the mitochondria, or heme imported from outside the 
cell. Heme synthesized in the mitochondria exits the active site of ferrochelatase in 
the matrix. It is possible that this heme immediately intercalates into the IMM and 
then is removed into the IMS by a heme binding chaperone, or is actively transported 
across the IMM, and then moved across the outer mitochondrial membrane (OMM) 
by a high affinity heme transporter (Figure 1, Pathways 1 & 2). 
 The sole mitochondrial heme exporter identified to date is the mitochondrial 
isoform of Flvcr1 (34, 35). Flvcr1, a member of the major facilitator superfamily of 
transporters, was initially identified as a plasma membrane heme exporter. Cats 
infected with feline leukemia virus, subgroup C (FeLV-C) develop aplastic anemia, 
with failure of erythropoietic blast-forming units to mature into colony-forming units, 
as binding of the virus to its receptor, Flvcr1, resulted in its internalization and 
inactivation (34). Early experiments showed that Flvcr1 could mediate the cellular 
export of heme and the heme analog, zinc mesoporphyrin (34). Mice lacking Flvcr1 
die either at E7.5 or between E14.5 and E16.5 due to impaired erythropoiesis, in 
keeping with in vitro studies showing that K562 cells fail to differentiate into 
erythroid-like cells when infected with FeLV-C (35). 
 Recently, Chiabrando et al identified a mitochondrial isoform of Flvcr1, 




transporter, Flvcr1b contains an alternative transcription start site, resulting in a 
shortened amino terminus containing a mitochondrial targeting signal. Depletion of 
Flvcr1b in HeLa cells results in accumulation of mitochondrial heme, indicating that 
Flvc1b plays a role in heme export from the mitochondria (36). Specific deletion of 
Flvcr1a in mice resulted in death at E14.5 and birth due to hemorrhage, edema, and 
skeletal abnormalities; however, erythropoiesis in these mice is normal (36). Thus the 
authors conclude that the lethality of the original Flvcr1 knockout mice was due to 
lack of heme export from the mitochondria by Flvcr1a, as that deletion targeted both 
Flvcr1 isoforms.  
  Numerous questions regarding heme exit from the mitochondria remain 
unanswered. It is not yet known if Flvcr1b resides on the mitochondrial IMM or 
OMM, with the possibility of another distinct mitochondrial heme exporter yet to be 
found.  It is also unclear whether Flvcr1b is actually located within the mitochondria 
or is associated with membranes that tether the mitochondria to other organelles. If 
mitochondrial heme export is indeed attenuated, how do Flvcr1
-/-
 embryos even 
survive until E14.5?  Does Flvcr1b only function in some cell types? No specific 
heme chaperones have been found to bind heme in the IMS, or to deliver heme to 
cytosolic hemoproteins. A number of cytosolic heme-binding proteins have been 
identified, including 22- and 23-kDa heme-binding proteins (HBPs) and the HBP 
homolog, SOUL (37-39). These proteins could serve as “sponges” for heme exiting 
the mitochondria, simultaneously protecting the cell from heme’s cytotoxicity and 




specific porphyrin-binding molecules perform the role of chaperoning heme in the 
cytosol, or if there are heme- and/or hemoprotein-specific pathways. 
 Presumably, heme imported into the cell, rather than solely heme exported 
from the mitochondria, could be bound by cytosolic heme chaperones and delivered 
to newly forming hemoproteins (Figure 1, Pathway 8). As such, plasma membrane 
heme importers could also be sources of heme for these enzymes. One such 
transporter is Hrg1. The heme-responsive paralogs, hrg-1 and hrg-4, were initially 
discovered as transmembrane domain-containing permeases upregulated in response 
to heme deficiency in C. elegans (40). HRG-4 is localized to the apical plasma 
membrane of the worm intestine and serves to import dietary heme into the animal 
(40, 41). HRG-1 localizes to lysosome-like vesicles in the intestine, and serves to 
mobilize heme stored in these compartments (40, 41). While hrg-4 does not appear to 
have homologs in other species, homologs of hrg-1, also called solute carrier 48 A1 
(SLC48A1) proteins, have been found in diverse organisms, including Leishmania 
spp., zebrafish, and mammals (40-43). Knockdown of hrg1 in zebrafish leads to 
anemia, although the genetic etiology for the anemia phenotype is not known. 
Transport of heme by hrg-1 and hrg-4 has been demonstrated directly using 
electrophysiological currents in Xenopus oocytes, and indirectly using heme-
dependent growth of C. elegans and Saccharomyces cerevisiae or uptake of heme 
analogs as indicators of heme import. 
 Mammalian Hrg1 has been shown to be expressed widely, with the highest 
expression in the brain, heart, kidney, and muscle, and with some expression in the 




progression, as its interaction with V-type ATPases is associated with changes in 
endocytic trafficking, extracellular acidification, altered glucose metabolism, and 
matrix metalloprotease activity (44, 45). Depletion of Hrg1 in MCF7 cells resulted in 
decreased invasiveness and migration capabilities in these cells. Hrg1 has also been 
found to be a target of nuclear factor (erythroid-derived 2)-like 2 (Nrf2), the 
antioxidant response transcription factor (46). In independent studies, human Hrg1 
colocalized with Lamp1 in lysosomes, and Hrg1 is found on the 
erythrophagolysosome in macrophages during red blood cell recycling (43, 47). Hrg1 
has been shown to mediate export of hemoglobin-derived heme from this 
compartment in macrophages. 
Heme Requirements in the Secretory Pathway 
 A variety of hemoproteins function in multiple components of the secretory 
pathway (Table 1). Lysosomal, peroxisomal, plasma membrane-targeted and secreted 
hemoproteins are folded and processed within the ER and Golgi, and thus the cell 
must have a means of transferring heme from the mitochondria into various 
subcellular membrane-bound compartments. These hemoproteins include 
prostaglandin synthases (COX1 and COX2) in the ER, myeloperoxidase in lysosome-
like azurophil granules, eosinophil peroxidase in eosinophil granules, catalase in 
peroxisomes, the plasma membrane proteins thyroperoxidase and ferric reductase, as 
well as numerous secreted proteins such as lactoperoxidase, fungal ligninase and 
chloroperoxidase, C. elegans hrg-3, Drosophila peroxidasin, RHBP (Rhodnius heme-




Almost nothing is known with regards to how these proteins obtain their heme 
cofactors. Given that the secretory and endocytic pathways are somewhat contiguous, 
with protein and lipid components being shuttled from location to another, it is 
feasible that heme need only be transported across a single membrane into the lumen 
of one such compartment, and from there can be mobilized to its intended destination 
by carrier proteins (Figure 1, Pathways 3-7) (48). For example, heme exiting the 
mitochondria may be transported into the ER, and from there be inserted into its 
target hemoprotein during protein folding, following which the holoprotein can then 
traffic to its target organelle. It is also possible that one or many heme chaperones 
exist in the secretory pathway for delivery of heme to hemoproteins in their 
destination compartments. The fact that no mechanism for targeting heme to the 
secretory pathway has been discovered hints that multiple mechanisms exist and can 
compensate for loss of a single such constituent. 
In contrast to the majority of hemoproteins in the secretory pathway, the 
maturation process of myeloperoxidase (MPO) has been well-characterized. MPO is a 
microbicidal protein generated by myeloid cells; its ability to chlorinate substrates 
enables it to generate hypochlorous acid from hydrogen peroxide [Reviewed in (49)]. 
This hemoprotein is extensively processed as it moves through the ER and Golgi; a 
single 80 kDa apo-proMPO peptide is converted to a glycosolated, heme-containing 
protein consisting of a 59 kDa heavy subunit and a 15.5 kDa light subunit that is 
targeted for secretion in its pro-form or for storage in azurophil granules as a mature 
protein (Reviewed in (50)). Early studies showed that disruption of the Golgi stacks 




improperly processed and remained in the pro-form (51). Moreover, treatment of cells 
with succinyl acetone to inhibit heme synthesis also resulted in MPO that was 
improperly processed, while the processing and trafficking of other lysosomal 
proteins remained unchanged. The authors concluded that that insertion of heme 
occurred in the ER, and that heme insertion was required for further processing, and 
that cleavage of MPO into its mature heavy and light subunits occurred in a post-ER 
compartment. Further support for these conclusions was provided by mutants, such as 
the R569W MPO mutant which is unable to acquire heme and remains trapped in an 
apo-form in the ER (a result suggesting that heme insertion is necessary for ER exit), 
and the Y173C MPO mutant, which does acquire heme but is unable to exit the ER 
(suggesting that heme insertion is mediated within the ER) (52, 53). The aberrant 
processing of these mutant forms of MPO is especially informative, as these results 
lack the confounding effects of brefeldin A treatment. 
Heme Delivery to the Secretory Pathway 
 Theoretically, there are a number of ways heme could enter the lumen of the 
secretory pathway. Heme released from the mitochondria could pass through the 
cytosol to be actively transported across the membrane of any subcellular 
compartment, (although no such transporter has been identified) (Figure 1, Pathway 
5). Heme imported into the cytosol could be moved into the secretory pathway in this 
manner as well. Heme entering the cell through an endocytic process (i.e. heme 
bound to hemopexin internalized via the low-density lipoprotein receptor-related 
protein (LRP)/CD91) could be trafficking to such compartments, with the possible 




Pathway 7). One appealing possibility is that nascent heme synthesized in the 
mitochondria could be shielded by vesicles entering the secretory pathway through 
direct contacts between the ER and mitochondrial membranes (Figure 1, Pathways 3 
& 4). 
 Contacts between the ER and mitochondrial outer membranes were observed 
over 40 years ago (54, 55). Jean Vance coined the term mitochondria-associated 
membrane (MAM) when she identified a functional relationship between these 
organelles to exchange phospholipids (56). With better subcellular fractionation 
techniques, and the advent of fluorescent imaging, especially the recent development 
of superresolution imaging, dynamic microdomains where mitochondrial membranes 
are tethered to ER membranes have been observed. These include the ER-
mitochondrion encounter structure (ERMES) in yeast and the previously mentioned 
MAMs, found in plants and animals (57, 58). These structures are involved in 
facilitating the transport of ionic calcium into the mitochondria, regulation of 
autophagy and apoptosis, and, most relevant to this review, the trafficking of lipids 
(59). The transport of phosphatidylserine from the ER to mitochondria has been 
demonstrated and it is hypothesized that other lipids are mobilized between these two 
organelles in a similar manner. Interestingly, two independent proteomic analyses of 
MAMs have detected the presence of coproporphyrinogen III oxidase, ferrochelatase, 
heme binding protein 1, and heme oxygenase 2 (60, 61). It is intriguing to postulate 
that these ER-mitochondria connections could serve as an axis for heme transport 




  Another possible mechanism for the trafficking of heme from the 
mitochondria to other organelles is the use of mitochondrial-derived vesicles 
(MDVs), which have been shown to traffic to both peroxisomes and lysosomes 
(Figure 1, Pathway 4) (62, 63). Initially, 70-100 nm vesicles were shown to deliver 
specific mitochondrial cargo proteins to peroxisomes. Other vesicles were later 
observed carrying cargo to lysosomes in response to increases in cellular oxidative 
stress (64, 65). As the processes of heme synthesis, mitochondrial respiration, and 
responding to oxidative stress are innately coupled by their shared metabolic 
pathways and mitochondrial location in the cell, it is possible to speculate that heme 
may be mobilized to these organelles via this mechanism. 
Heme Trafficking During Physiological Processes 
Heme Mobilization During Erythrophagocytosis 
 Much like the birth of red blood cells (RBCs), which differentiate from 
hematopoietic progenitors in the presence of nurse macrophages, the final moments 
of an RBC are spent in the care of a macrophage. Human RBCs have a lifespan of 
about 120 days, after which they become senescent and are recycled by macrophages 
of the reticuloendothelial system (RES) found in the spleen and liver [Reviewed in 
(66)]. This process - phagocytosis of RBCs and the breakdown of billions of 
molecules of hemoglobin - is termed erythrophagocytosis (EP) (Figure 1.2). EP is 
essential, as the bulk of iron required for the synthesis of new hemoglobin (~25 
mg/day) derives from the recycling of RBCs (67). By contrast, only about 1 mg per 







Figure 1.2: Heme transport pathways during erythrophagocytosis. 
Pathways for iron and heme recycling during erythrophagocytosis. Unknown 
pathways are indicated with a (?). Hrg1 imports heme into the cytoplasm from the 
erythrophagolysosome. A portion of heme is (1) degraded by Hmox1 and iron 
released is either stored in ferritin (Ftn) or exported by ferroportin (Fpn). (2) Some 
heme may be exported via a plasma membrane heme transporter such as Flvcr1a, or 




vital role in this process, freeing iron from its protoporphyrin ring, and enabling the 
release of this iron for reuse. Hmox1
-/-
 mice suffer from anemia, reduced serum iron, 
and accumulation of iron in the spleen and liver, as the ability to recycle heme-iron in 
these mutants is almost completely crippled (68). In vitro experiments showed that 
Hmox1
-/-
 macrophages die when fed RBCs, and that splenic and liver macrophages 
are absent in Hmox1
-/-
 mice (69). 
 Heme extracted from RBCs was postulated by some to be degraded by 
Hmox1 inside the phagolysosome (70). Subsequently, the newly-released iron was 
either stored in ferritin (Ftn) or returned to the circulating pool of iron via the cellular 
iron exporter, ferroportin (Fpn). A major problem with this model is that Hmox1, 
while localizing to the ER via a C-terminal transmembrane segment, has been shown 
to be oriented with its active site facing the cytosol (71). Furthermore, the pH 
optimum for heme catabolism by Hmox1 is closer to physiological pH (pH 7.6) than 
lysosomal pH and maximal Hmox1 activity requires biliverdin reductase (72, 73). 
Studies have shown that heme oxygenases are not present on the phagolysosomal 
membrane, even though this membrane is partially derived from the ER (47). Thus 
Hmox1 likely does not have access to heme within the phagolysosomal compartment, 
suggesting that heme must exit this membrane compartment before degradation. 
 Hrg1, which has been shown to localize to endocytic compartments in 
mammalian cells, has recently been reported to transport heme across the 
phagolysosomal membrane (43). Hrg1 is expressed in RES macrophages and is 
upregulated at both the mRNA and protein level in the presence of heme and during 




(BMDMs) treated with damaged RBCs, as well as in the livers of mice treated with 
heme, damaged RBCs, or the hemolysis agent phenylhydrazine (43). During EP, 
Hrg1 accumulates on the membrane of the phagolysosome, and when Hrg1 is 
depleted by siRNA, BMDMs are incapable of upregulating the machinery normally 
required to deal with the influx of heme and iron (including Hmox1, Ftn, Fpn, and 
Hrg1 itself) indicating a lack of heme export from the phagolysosome. Interestingly, a 
polymorphism of Hrg1 (P36L mutation) associated with anemia in four patients was 
shown to be defective in heme export in both a yeast model of heme transport, and 
during EP in BMDMs (43). These experiments used a heterologously expressed 
hemoprotein reporter, horseradish peroxidase (HRP), targeted to the Golgi to 
interrogate cellular heme availability – and showed that heme derived from recycled 
RBCs could be incorporated into an apohemoprotein by assaying HRP activity in 
BMDMs during EP. This opens the intriguing possibility that not all heme liberated 
during EP is degraded via Hmox1, and that a portion can be reused in the cell or 
exported by a transporter like Flvcr1a. 
Heme Trafficking During Embryogenesis 
 It has long been known that metal homeostasis plays a vital role in embryonic 
and post-embryonic development (74). For example, mouse pups from iron- or 
copper-depleted dams experience developmental and neurological abnormalities 
whose severity is dependent on the timing and extent of the maternal deficiency. A 
number of metal transporters are embryonic lethal when targeted for gene knockout. 
There are two interconnected factors that need to be taken into account: a) maternal 




these nutrients; and b) metal transport within the embryo as pluripotent cells grow 
and differentiate into tissues. 
 The respective phenotypes of the Flvcr1 and Flvcr1a knockout mice provide 
some insight into the role of heme transport during embryogenesis. As previously 
mentioned, Keel et al report that homozygous Flvcr1 knockout pups (which lack both 
the mitochondrial and plasma membrane isoforms of Flvcr1) are found dead at either 
E7.5 or later at E14.5-E16.5 (35). The authors infer from this observation that Flvcr1 
is required for definitive erythropoiesis (which begins at ~E12) and not embryonic 
erythropoiesis. In support of this, they mention that yolk sac-derived erythroblasts do 
not express Flvcr1 and appear normal in Flvcr1
-/- 
mice. If the cause of mortality in 
Flvcr1
-/-
 mice is defective heme export from the mitochondria, then we must wonder 
about the source of heme used for embryonic erythropoiesis. It may be that this heme 
is maternally-derived via one or more heme importers in the early embryo. However, 
it is known that homozygous ferrochelatase knockout embryos can be detected at the 
E3.5 preimplantation stage, but are reabsorbed and undetectable at E9-E10 - a 
phenotype also observed for uroporphyrinogen decarboxylase knockout animals [J. 
Phillips, personal communication and (75, 76)]. Although the ferrochelatase null 
phenotype should overlap with the Flvcr1
-/-
 phenotype, as both would cause heme 
deficiency in the cell, this is not the case. The greater severity of the ferrochelatase 
mutant hints that maternal heme cannot completely support embryonic development, 
and that a small portion of heme can exit the mitochondria in the Flvcr1
-/-
 mice in an 




 Interestingly, deletion of the plasma membrane-localized Flvcr1a isoform also 
causes embryonic lethality (36). This lethality, due to hemorrhages, edema, and 
skeletal malformations, is observed later during development, usually between E14.5 
and birth. Chiabrando et al speculate that many of these defects, also observed in 
mice with defects in endothelial integrity, are due to heme buildup within endothelial 
cells leading to widespread oxidative stress and hypoxic conditions in developing 
embryos. Interestingly, Flvcr1b is upregulated in these mice, presumably leading to 
increased cytoplasmic heme as evidenced by increased levels of Hmox1. Thus, 
plasma membrane heme export is an essential regulator of heme homeostasis during 
development. 
 While intercellular and intracellular heme transport are critical during 
embryogenesis, maternal transfer of heme to offspring may also play a critical role in 
embryonic development. This process has been demonstrated in C. elegans, where the 
small peptide HRG-3 serves as a chaperone for heme delivery to developing embryos 
and extraintestinal tissues (77). When the worm is heme deprived, expression of hrg-
3 in the intestine is upregulated >300-fold. HRG-3 is processed in the secretory 
pathway into a 45-amino acid chaperone which binds heme in a stoichiometry of 1:2 
(heme:protein). Mature HRG-3 is secreted into the worm’s circulation and taken up 
by extracellular tissues and developing oocytes. When hrg-3 null worms are grown 
under heme limiting conditions, they show embryonic lethality and delayed growth, 
indicating a role for hrg-3 in the distribution of heme from the intestine during early 





 ATP-binding cassette (ABC) transporters form one of the largest protein 
superfamilies and are found in all three domains of life. ABC transporters are active 
transporters that utilize ATP-derived energy to transport a diverse range of substrates 
across biological membranes. These substrates are often referred to as allocrites, in 
order to distinguish them from biochemical substrates, which unlike transport 
substrates, are enzymatically modified by the protein acting upon them (78) The 
human genome encodes 49 ABC transporters, divided into seven subfamilies, termed 
ABCA through ABCG, at least eighteen of which cause disease when mutated (79). 
ABC transporters possess a basic architecture consisting of two 
transmembrane domains (TMDs) which form the transport channel, as well as two 
cytosolic nucleotide-binding domains (NBDs) which hydrolyze ATP. ABC 
transporters have been shown to transport assorted allocrites, including sugars, amino 
acids, peptides, vitamins, ions, hormones, as well as xenobiotics such as antimicrobial 
and chemotherapeutic agents. In eukaryotes, the vast majority of ABC transporters 
have been shown to function as effluxers (with the exceptions listed in Table 1.2) 
[Reviewed in (80)]. As such, these transporters are excellent candidates to serve as 
eukaryotic heme exporters. 
ATP Hydrolysis by Nucleotide Binding Domains  
ABC transporters, from bacteria to humans, are characterized by conserved 
motifs, including the LSGGQ signature, and Walker A and Walker B motifs (Figure 
1.3A). These motifs function in the NBD to facilitate ATP hydrolysis, and are 
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Figure 1.3: Conserved Motifs in Nucleotide Binding Domains.  
(A) Cartoon representation of a nucleotide binding domain (NBD). Conserved 
sequences are in parenthesis, using the one letter code for amino acids (x, any residue, 
ϕ, hydrophobic residue.) Motifs involved in nucleotide binding are shown in red. (B) 
Structure of a NBD dimer [based on Geobacillus stearothermophilus ArtP, PDB code 
(2OUK)] indicating the location of the Walker A and signature motifs shown in (A). 
Two ATP molecules are shown in purple (space fill representation). One monomer, 
the A chain, is shown in yellow, and the other monomer, the B chain, is shown in 




NBD has a bilobed structure, consisting of both a RecA-like subdomain (also known 
as the core subdomain), containing the Walker A/P loop and Walker B motifs (that 
contribute to nucleotide binding), and an alpha-helical subdomain, which contains the 
Q-loop and the signature LSSGQ sequence. The Q-loop senses the γ-phosphate, binds 
a divalent cation (usually Mg2
+
), and attacks water. Like the Q-loop, the signature 
motif interacts with the γ-phosphate and is also involved in ATP hydrolysis.  
The nucleotide binding domains adopt a head-to-tail conformation, where the 
Walker A motif of one NBD interacts with the signature motif of the second NBD, 
and the Walker A motif of the second NBD interact with the signature motif of the 
first NBD (Figure 1.3B). In this manner, two ATP hydrolysis sites are formed as the 
two halves of the dimer bind together, with two molecules of ATP sandwiched in the 
interface.  
Mechanism of Transport 
 Transport by ABC transporters can be broken down into discrete stages: 
substrate recognition by the TMDs, ATP hydrolysis by the NBDs, and the 
conformational change which facilitates translocation. There are a number of models 
that seek to describe these steps. One early model, called the alternating access 
model, postulates that the transporter can adopt either an inward-facing or outward-
facing conformation; these conformations have different affinities for the allocrite, 
setting up a gradient across the membrane. In this way, ATP hydrolysis fuels cycling 
through the two conformations, facilitating transport (87). The second model, called 
the processive clamp model, outlines six steps of transport. First, the protein exists in 




substrate binds to the TMDs. Third, there is an ATP-dependent association of the 
NBDs, which occurs concomitantly with the fourth step, substrate release. Fifth, ATP 
is hydrolyzed by the NBDs, resulting in the final sixth step, dissociation of the two 
NBDs, returning the transporter to its original state (88, 89). 
 A number of subtleties must be added to these models. First, it is known that a 
single transporter can be stimulated to different degrees by different drugs (90, 91). 
Thus, it is unlikely that these transporters exist in one of two binary states, as a more 
complex signal is clearly capable of being transmitted from the TMDs to the NBDs. 
Second, certain transporters (e.g. P-glycoprotein/ABCB1) have been shown to exhibit 
basal ATPase activity in the absence of substrate, while other transporters (such as 
yeast Pdr5) only exhibit basal activity (i.e. are not stimulated by their substrates) (90, 
92). Therefore, the presence of substrate, and the subsequent dimerization of the 
NBDs, is not required for ATP hydrolysis, and the dimerization of the NBDs does not 
guarantee an increase in ATPase activity. Interestingly, the ATP hydrolysis site in one 
NBD interface has degenerated in Pdr5, which partially explains how this transporter 
is only capable of basal activity. A similar asymmetry in the NBDs is found in the 
human ABC transporters CFTR/ABCC7 and TAP1 (93, 94). Third, mutational 
analysis has identified residues in the NBDs that alter the substrate selectivity of 
certain transporters (95, 96). Thus, at least for a number of ABC transporters, the 
NBDs do play some role in substrate selection. Last, a study of at least one bacterial 
ABC transporter, HorA, demonstrated that reconstitution of the protein in liposomes 
changed its function relative to the protein in its native membrane. While HorA 




can conclude that, at least for certain transporters, the local environment plays a role 
in the communication between the TMDs and NBDs. 
 A feature of many ABC transporters is their ability to transport a wide array of 
allocrites. This can be demonstrated in P-glycoprotein (P-gp), where certain 
substrates only compete with Hoechst 33342 transport, and not rhodamine transport, 
and vice versa (91). Other drugs compete with both, indicating that various drugs 
occupy different binding sites in the transporter. Structural and biochemical analysis 
of multidrug transporters indicate that a large, hydrophobic drug-binding pocket 
exists, but can be divided into smaller sub-sites with varying affinities for different 
drugs (98, 99). A complete understanding of how these transporters recognize their 
substrates has yet to be elucidated. 
ABC Transporter Structure 
 The first structure of a full ABC transporter was published by Kaspar 
Locher’s group in 2006 (100). This group determined the 3 Å structure of 
Staphyloccocus aureus Sav1866, a homolog of human ABCB1 (P-
glycoprotein/MDR1) and TAP1 transporters. The full transporter is 120 Å long, 65 Å 
wide, and 55 Å deep in the outward facing, ATP-bound state. It consists of twelve 
alpha helixes, which form the transmembrane domains and intracellular loops (ICLs) 
which extend ~25 Å away from the plasma membrane, and two symmetrical 
nucleotide binding domains in a head-to-tail arrangement (Figure 1.4A and B). 
The two halves of the protein showed extensive interactions, with the two 
NBDs cooperatively forming two ATP-hydrolysis sites, and portions of the ICLs 








Figure 1.4: Sav1866 Structure.  
(A) Structure of full length Sav1866 from Staphylococcus aureus, with each half 
(subunit) of the protein coloured yellow or turquoise. Bound ADP is shown in ball-
and-stick representation. The view depicts the membrane-embedded “ears”; the grey 
box shows the probable location of the lipid bilayer. (B) Stereo view of the Sav1866 
structure rotated 90° with respect to (A). The transmembrane helices of one subunit 
are numbered. Note that TMD1 is the only TMD that does not extend past the 
membrane. TMDs, transmembrane domains; NBDs, nucleotide-binding domains; 
ICL, intracellular loops; ECL, extracellular loops; N-ter, amino terminus; C-ter, 




plane. These helices, termed ‘coupling helices’, engage in domain swapping with the 
NBD of the other half of the transporter. For example, the ICL formed between 
transmembrane segments 4 and 5 from TMD1 interacts with NBD2 (Figure 1.3B). 
This interaction is thought to aid in transmitting conformational changes due to 
nucleotide binding from the NBDs to the TMDs. This is consistent with previous 
studies showing that these components interact and are required for optimal transport 
activity (101, 102). Interestingly, domain swapping of the coupling helices does not 
occur in the structure of ABC importers that have been solved thus far. 
 The translocation pathway in this structure does not connect to the cytoplasm; 
rather, it opens into the extracellular space. It is lined with polar and charged residues, 
which the authors conclude reflect a mechanism for the extrusion of hydrophobic 
allocrites. Additionally, residues from all transmembrane helices contribute to the 
surface of the pathway through the transporter, and no high-affinity binding sites are 
found in this channel. 
 Since the publication of the Sav1866 structure, a number of eukaryotic ABC 
transporter structures have been solved. The 3.8 Å structure of mouse p-glycoprotein 
(P-gp or ABCB1/MDR1) was published in 2009 (98). P-gp is of particular clinical 
interest in that it has unusually broad specificity, transporting chemically diverse 
compounds ranging from 330 to 4000 daltons. This structure was solved in the 
inward-facing conformation, with the two NBDs separated by 30 Å. However, the 
structure does reveal a large cavity open to both the cytoplasm and the inner leaflet of 
the membrane, allowing hydrophobic molecules found in the membrane direct access 




residues, to facilitate transport of hydrophobic allocrites. P-gp was also crystallized in 
the presence of two transport substrates, two cyclic peptides (QZ59-RRR and QZ59-
SSS). P-gp can distinguish between these two stereoisomers, as they are shown to 
bind different residues. Indeed, upon comparing amino acids in contact with QZ59-
RRR, QZ59-SSS, and another substrate, verapamil, the authors note that only two out 
of a total thirty three drug-binding residues are shared by all three allocrites. 
 Recently, the 3 Å structure of C. elegans P-gp (pgp-1) in the inward-facing 
conformation was published (103). Similar to mouse P-gp, the transport cavity is 
open to both the cytosol and the inner membrane leaflet. Given that worm P-gp shows 
100- to 4,000-fold more allocrite-stimulated ATPase activity in the presence of 
membranes than in the presence of detergents, the authors conclude that indeed P-gp 
substrates are transported more efficiently directly from the membrane. Additionally, 
the authors show that the contact points between the intracellular loops and NBDs are 
similar to those in mouse P-gp; this is reflected in the high degree of sequence 
conservation (approaching 80% identity) between worm and mouse P-gp in these 
regions. 
Multidrug Resistance Protein 5 (MRP5) 
 The focus of this work, MRP5, was discovered by three independent groups 
looking to identify novel ABC transporters (104-106). MRP5 transcripts were 
detected in all human tissues assayed, including the spleen and small intestine, with 
the highest expression in skeletal muscle and brain (105). MRP5 localizes to the basal 
membrane of syncytiotrophoblasts and fetal vessels of the placenta (107). In the 




cells (108). MRP5 localizes to intracellular structures in human bronchial epithelial 
cells (109). 
 Early on it was demonstrated that MRP5 is an organic anion transporter, 
capable of effluxing acidic, organic dyes and glutathione (GSH), as well as nucleotide 
monophosphate analogs (110). Soon afterward, it was demonstrated that MRP5 
transported the cyclic nucleotides cGMP and cAMP with Km values of 2.1 and 379 
μM, respectively (111). The affinity of MRP5 for cAMP and cGMP appears to vary 
depending on the model system used (112). No resistance to cisplatin or doxorubicin 
was observed in MRP5-transfected cells (110, 113). In a review, Borst et al conclude 
that it is unlikely that MRP5 contributes substantially to drug resistance (114); 
however, it should be noted that MRP5 is upregulated in certain cancer types (115-
117). In the same review, published in 2006, the authors note that the function of 
MRP5 remained a mystery.  
Summary 
 Heme is ubiquitously required by living organisms as a prosthetic group in 
proteins (118). Heme is synthesized in the mitochondrial matrix but must be 
trafficked to various subcellular compartments for incorporation into hemoproteins in 
the cytoplasm, ER/Golgi, lysosomes, and peroxisomes (119). However, unescorted 
movement of heme within a cell is inherently hazardous due to the reactivity of free 
heme. It follows that cells must have specific pathways for the directed movement of 
heme within and between cells and tissues but these intra- and intercellular pathways 




We have exploited Caenorhabditis elegans as a genetic model organism 
because this roundworm is a heme auxotroph (120). C. elegans is dependent on both 
maternally-derived heme for embryonic development, as well as heme acquired from 
the diet during larval growth (120). How does intestinal heme, derived from the 
environment, get delivered to hemoproteins in extra-intestinal tissues? Are these 
intercellular heme transport pathways found in vertebrates? With this work, we show 
that a multidrug resistance protein, MRP-5/ABCC5, likely acts as a cellular heme 
exporter and is essential for viability in C. elegans.  This conclusion is supported by 
our genetic studies in yeast, C. elegans, zebrafish, and mammalian cell culture models 
which ascribe a physiological role for a multidrug resistance protein in regulating 










 Worms were maintained in axenic liquid mCeHR2 medium with continuous 
shaking or on nematode growth medium (NGM) plates seeded with OP50 or 
HT115(DE3) bacteria at 15°C or 20°C unless noted otherwise (121). NGM plates 
were 3 g/L NaCl, 2.5 g/L peptone, 20 g/L agar, 5 mg/L cholesterol, 0.1 M CaCl2, 0.1 
M MgSO4, and 25 mM KH2PO4. Routine maintenance, synchronization, crosses, and 
observation of C. elegans were described by Epstein and Shakes (122). 
Synchronization of Worms 
Worms were collected from plates using M9 buffer (86 mM NaCl, 42 mM 
Na2HPO4, 22 mM KH2PO4, and 1 mM MgSO4) and washed three times to remove 
bacteria. Worms from liquid mCeHR-2 medium were harvested by centrifugation at 
800 x g for 5 minutes (121). The medium was aspirated and 0.1 M NaCl was added. 
The worms were allowed to settle on ice for 5 minutes. The supernatant was aspirated 
and gravid worms remaining were bleached using a 1.1% sodium hypochlorite and 
0.55 M NaOH solution. After eggs were observed being released from adult worms, 
the mixture was centrifuged (800 x g, 1 minute) and washed twice with sterile water. 





 Worms strains used in this study are listed in Appendix I. VC1599, WM118, 
NR222, and VP303 strains were obtained from the Caenorhabditis Genetics Center 
(CGC, USA). The deletion strain mrp-5(ok2067) was obtained by crossing the 
balanced strain VC1599 to wild-type N2 worms on plates seeded with OP50 grown in 
media supplemented with 500 μM heme. F2 progeny were analyzed by single worm 
PCR to identify homozygous mutants and wild-type brood mates. Genotyping 
primers for the mrp-5(ok2067) allele can be found in Appendix II. Homozygous mrp-
5 worms were outcrossed three times to N2 worms, and maintained on plates seeded 
with OP50 bacteria grown in LB broth supplemented with >200 μM heme. 
Gateway Cloning 
 The mrp-5 transcriptional and translational reporter constructs were generated 
using Multisite Gateway recombination (Invitrogen). C. elegans promoters, ORFs, 
and 3’ untranslated regions were amplified with sequence-specific Gateway attB 
primers. PCR products were recombined into donor plasmids, and then into 
expression plasmids, according to the manufacturer’s instructions (Invitrogen). 
Generation of Transgenic Worms 
 Reporter constructs, along with the unc-119 rescue construct, were introduced 
by microparticle bombardment into unc-119(ed-3) worms using the PDS-1000 
particle delivery system (Bio-Rad) (123). At least two transgenic worm lines were 




Single Worm PCR 
 For single worm PCR, worms were lysed in lysis buffer (50 mM KCl, 10 mM 
Tris-HCl, 2.5 mM MgCl2, 0.45% NP-40, 0.45% Tween-20, 0.01% gelatin, 1 mg/ml 
proteinase K) by incubation for 2 hours at -80°C, 1 hour at 65°C, and 30 min at 95°C. 
Worm lysates were added to PCR reactions with primers to detect wild-type and 
mutant alleles. Genotyping primers for mrp-5(ok2067) are listed in Appendix II. 
RNA Extraction, cDNA Synthesis, and Quantitative Real Time PCR 
 Synchronized worms were grown at varying heme concentrations (1.5-20 μM 
heme) for two generations and then harvested at the late L4 stage. Worms were 
washed in M9 buffer, lysed using Lysing Matrix C beads (MP Biomedicals) in a 
FastPrep-24 Beadbeater (MP Biomedicals). Total RNA was isolated with the TRIzol 
reagent (Invitrogen), purified by chloroform extraction, and DNase-treated with 
TURBO DNase (Life Technologies). RNA quality was monitored using gel 
electrophoresis and by measuring the absorbance at 260 nm and 280 nm using a 
spectrophotometer (Shimadzu).  
 After resuspension in Tris buffer (pH 8.0), 2 μg of total RNA was used to 
synthesize cDNA using oligo(dT) primers and the SuperScript III First-Strand 
Synthesis System (Invitrogen), according to manufacturer’s instructions. Quantitative 
real-time PCR (qRT-PCR) was performed in triplicate using SYBR green as the 
detection dye in an iCycler iQ Multi-Colour Real-Time PCR Detection System (Bio-





 RNAi experiments were performed by feeding the worms bacteria expressing 
double-stranded RNA (dsRNA) complimentary to the gene of interest. For RNAi 
feeding, the clones for mrp-2, mrp-4, mrp-5, mrp-6, and the C. elegans FLVCR 
homologs were taken from the Ahringer library (124). The clone for mrp-8 was taken 
from the Vidal library (125). The clones for hrg-1 and hrg-4 were generated 
previously as in (40). The clones for mrp-1, mrp-3, mrp-7, and the mrp-5 3’ UTR 
were generated by cloning portions of their transcripts into the L4440 plasmid (Fire 
Vector Kit, Addgene) which were then transformed into the RNase III-deficient 
bacteria, HT115(DE3). Bacterial cultures were grown and then spotted onto NGM 
plates containing 50 μg/mL carbenicillin, 12 μg/mL tetracycline, and 2 mM 
isopropyl-β-D-thiogalactopyranoside (IPTG). L1 larvae were placed on RNAi plates 
and incubated at 15°C or 20°C. Phenotypes were investigated as necessary after at 
least 72 hours.  
Heme Analog Assays 
 Zinc mesoporphyrin, and gallium protoporphyrin IX were purchased from 
Frontier Scientific, Inc (Logan, UT). Heme analog solutions were prepared as 10 mM 
stock by dissolving in 0.3 M NH4OH and pH-adjusted to 8.0 by addition of HCl. To 
assess uptake of ZnMP, synchronized L1 worms were grown on NGM plates seeded 
with OP50 or RNAi bacteria until they reached L4 stage. Worms were washed off 
plates and rinsed three times in M9 buffer to remove bacteria. Worms were incubated 
in mCeHR2 medium with 60 μM ZnMP for 3 hours, rinsed to remove excess ZnMP, 




levamisole and imaged using a Leica DMIRE2 epifluorescence/DIC microscope. 
Images were obtained using a Retiga 1300 cooled mono 12-bit camera and quantified 
using SimplePCI software (Compix Inc). 
 To assess toxicity of GaPPIX, synchronized L1 worms were grown on NGM 
plates seeded with OP50 or RNAi bacteria until they reached L4 stage. Worms were 
washed off plates and added to NGM plates containing various concentrations of 
GaPPIX and seeded with OP50 or RNAi bacteria. After 48 hours, worms were scored 
as dead if they were unresponsive to a physical stimulus. 
Quantification of Fluorescence using COPAS BioSort 
 Worms were grown from the L1 larval stage to the early adult stage on RNAi 
plates. Worms for each condition were analyzed for time of flight (length) and 
extinction (optical density) using a COPAS BioSort (Union Biometrica, Holliston, 
MA) with gating parameters for mixed worm populations as in Chen et al (77). The 
settings for measuring GFP intensity in IQ6011 (Phrg-1::GFP)  were gain = 2.5 and 
PMT voltage = 400 and in IQ8031 (Phrg-3::GFP)  were gain = 2.5 and PMT voltage = 
600. The settings for measuring YFP intensity in IQ8122 (Phrg-2::HRG-2-YFP)  were 
gain = 2.5 and PMT voltage = 600. 
Growth Assays 
 To assay embryonic lethality, worms were grown to gravid stage on NGM 
plates seeded with OP50 bacteria. (Wild-type N2 worms were grown on OP50 
bacteria with no added heme, while mrp-5(ok2067) worms were grown on OP50 with 




containing IPTG, tetracycline, and carbenicillin that were seeded with vector control 
or RNAi bacteria with or without added heme, and allowed to reach young adult 
stage. Adult worms were moved to fresh plates, allowed to lay eggs for 24 hours, and 
then removed. Hatched L1 worms and eggs were counted 24 hours after removal of 
adults; eggs that did not hatch after 24 hours were considered dead.  
To assay larval development, wild-type N2 and mrp-5(ok2067) worms were 
grown to gravid stage on NGM plates seeded with OP50 bacteria grown in LB broth 
with the addition of >200 μM heme. Synchronized L1 larvae were seeded onto NGM 
plates seeded with OP50 bacteria grown with or without 200 μM added heme. Worms 
were incubated and DIC images were obtained when wild-type N2 worms reached 
gravid stage (4 days). 
Yeast Methods 
Strains and Growth 
 S. cerevisiae strains used in this study contained the hem1∆ mutation in the 
W303 and YPH499 strains and have been described previously (41, 126, 127). Cells 
were maintained at 30°C in yeast peptone dextrose (YPD) media supplemented with 
250 μM δ-aminolevulinic acid (ALA) unless otherwise noted (Frontier Scientific). 
The hem1Δ fre1Δfre2ΔPGK1-FRE1 strain was maintained on synthetic complete 
(SC) plates (-Trp) containing 2% w/v glucose supplemented with 250 μM ALA. 
Cloning and Transformation 
 To generate yeast expression plasmids, a yeast codon-optimized and flag-




containing BamHI and XbaI sites, digested, and ligated into the pYES-DEST52 
vector (Invitrogen) digested with the same enzymes. Human MRP5 (Genbank 
#U83661) was amplified with primers containing BglII and SpeI sites (with and 
without a C-terminal HA tag), digested, and ligated into pYES-DEST52 digested with 
the compatible cohesive enzymes, BamHI and XbaI. The Pug1p ORF in pYES-
DEST52 was a gift from Caroline Philpott (National Institutes of Health). 
Growth Assays 
 The liquid and dilution spot assays were performed as described previously 
(41, 126, 127). Plasmids containing potential heme transporters were transformed into 
hem1Δ yeast using the lithium method (128) and selected on 2% w/v glucose SC (-
Ura) plates supplemented with 250 μM ALA. Ten colonies were streaked onto 2% 
w/v raffinose SC (-Ura) plates supplemented with 250 μM ALA for 48 hrs. Cells 
were grown in 2% w/v raffinose SC (-Ura) liquid medium without heme or ALA for 
at least 12 hours to deplete endogenous heme. For the liquid growth assay, cells were 
then diluted to OD600 of 0.05 in 96-well plate format, and grown in a humidity 
chamber at 30°C for 24 hours. OD600 was measured using a Synergy HT microplate 
reader (Biotek). For the dilution spot assay, cells were diluted to OD600 of 0.2, serially 
diluted, and spotted in 10 μl aliquots onto 2% w/v raffinose SC (-Ura) plates 
supplemented with varying amounts of heme or ALA and 0.4% w/v galactose to 
induce gene expression from the GAL1 promoter. Plates were incubated for 3 days 
before imaging. To assay aerobic growth exclusively, yeast were induced with 2% 
galactose in the of ALA, and then spotted onto plates containing indicated heme or 





 Plasmids were co-transformed into the hem1Δ strain with the reporter plasmid 
pRS314m-CYC1-LacZ. Transformants were selected on 2% w/v glucose SC (-Ura -
Trp) plates supplemented with 250 μM ALA. Cells were heme-depleted by growth in 
2% w/v raffinose SC (-Ura -Trp) liquid medium with no added ALA for 12 hours. 
Cells were then resuspended to an OD600 of 0.1 in 2% w/v raffinose SC (-Ura -Trp) 
liquid medium supplemented with varying concentrations of heme or ALA and 0.4% 
w/v galactose for gene induction and cultured overnight. Cells were washed in 
washing buffer (2% BSA, 0.1% Tween-20 in 2X PBS), lysed, and assayed for β-
galactosidase activity as described elsewhere (129). Protein concentrations for each 
lysate were measured and β-galactosidase activity was normalized to total protein. 
Ferric Reductase Assay 
 Plasmids were transformed into the hem1Δ fre1Δfre2ΔPGK1-FRE1 strain as 
above and selected using 2% w/v glucose SC (-Ura -Trp) plates supplemented with 
250 μM ALA. Cells were restreaked on 2% w/v raffinose SC (-Ura -Trp) plates 
supplemented with 250 μM ALA for 2 days. Cells were heme depleted by growth is 
in 2% w/v raffinose SC (-Ura -Trp) liquid media with no added ALA for at least 12 
hours. Cells were resuspended in 2% w/v raffinose SC (-Ura -Trp) liquid medium 
supplemented with 0.4% w/v galactose, 0.1 mM Na2S, and varying concentrations of 
heme or ALA and grown overnight. Cells were washed repeatedly in washing buffer, 
then in reaction buffer (5% glucose, 0.05 M sodium citrate buffer, pH 6.5) and 
resuspended in reaction buffer. The OD of the suspended cells was measured, equal 




buffer) was added (T=0 min), and cells were incubated at 30°C until a red color 
developed. OD535 and OD610 were measured and ferric reductase activity (nm/10
6 
cells/min) was determined. 
Immunofluorescence 
 Transformed yeast were grown in 2% w/v raffinose SC (-Ura) liquid medium 
supplemented with 0.4% galactose and 250 μM ALA, and fixed with 4% 
formaldehyde for 1 hour at room temperature. Cells were washed twice with 
phosphate buffered saline (PBS) and resuspended in 1.2 M sorbitol with 1 mM 
dithiothreitol and treated with 30 μg zymolase at 30°C for 30 minutes. The resulting 
spheroplasts were washed twice with sorbitol buffer. Spheroplasts were added to 
poly-L-lysine-coated 8-well slides, incubated with anti-Flag or anti-HA antibody, and 
then Alexa-488 conjugated secondary antibody. Each sample was covered in ProLong 
Antifade solution (Invitrogen) and a coverslip and allowed to dry before analysis by 
confocal microscopy. 
Mammalian Methods 
Mouse Strains and Care  
 All animal experiments were approved by the University of Maryland 
Institutional Animal Care and Use Committee. FVB/NJ mice were purchased from 
Jackson Laboratories (Bar Harbor, ME). Mrp5 mutant mice were a gift from Dr. Piet 
Borst (Netherlands Cancer Institute). Mouse pups and cell lines were genotyped for 




Generation of Immortalized Fibroblasts 
 To generate mouse embryonic fibroblasts (MEFs), E12.5 embryos were 







cell lines were generated by retroviral infection of MEFs with conditioned media 
from Ψ2-U195 cells producing the SV40 large T antigen as in (132). SV40 large T 
antigen expression was confirmed in MEFs by Western blot and cell lines were 
genotyped using the Mrp5 primers listed in Appendix II.  
Mammalian Cell Culture 
 Mammalian cells were cultured at 37°C in a humidified incubator with 5% 
CO2. MDCKII cells and MEFs were grown in Dulbecco’s modified Eagle medium 
(DMEM) supplemented with 10% FBS and 1% penicillin/streptomycin/glutamine for 
cell culture studies. MDCKII cells expressing human MRP5 were a gift from Piet 
Borst (Netherlands Cancer Institute). 
 Isolation and culture of bone marrow from the femurs of C57BL/6 mice was 
carried out as described elsewhere (133). Differentiation of bone marrow monocytes 
was carried out in differentiation medium including L-929 cell-conditioned media 
(LCM) as a source of granulocyte/macrophage colony-stimulating factor (134). 
Differentiation media is RPMI 1640 (Invitrogen) supplemented with 30% LCM, 20% 
heat-inactivated fetal bovine serum (FBS, Atlanta Biologicals), 100 U/ml penicillin, 
100 mg/ml streptomycin, and 2 mM L-glutamine (Invitrogen). L-929 cells were 
purchased from the American Type Culture Collection (ATCC). For production of 
LCM, L-929 cells were grown in the presence of RPMI 1640 supplemented with 10% 




glutamine for 30 days. Media was collected by sterile filtration and stored at −20°C. 
In all experiments, BMDMs were cultured in the presence of heme-depleted serum 
(HD) media as untreated control. HD media was prepared similarly to differentiation 
media with the exception of substituting 20% heme-depleted FBS for FBS. Heme 
depletion was achieved by treating FBS with ascorbic acid for ∼7–8 hr, followed by 
dialysis against PBS and filter sterilization. The depletion of heme from the serum 
was monitored by measurement of the optical absorbance at 405 nm. Depletion was 
considered successful when the absorbance of serum was reduced at least 50% 
following ascorbic acid treatment (135). 
DNA Cloning 
The human MRP5 ORF cut with BglII and SpeI was cloned into 
pcDNA3.1(+)zeo and pEGFP-N1 cut with BamHI and XbaI for mammalian 
expression. Plasmids were transfected into MDCKII cells and MEFs using 
Lipofectamine transfection reagent (Invitrogen).  
Immunofluorescence 
 For MRP5 staining, cells were fixed in acetone, blocked in 5% BSA in 1X 
PBS, incubated with the primary antibody (anti-MRP5, 1:40 in blocking solution), 
secondary antibody (Alexa-conjugated anti-rat, 1:3000 in blocking solution), 
subjected to DAPI staining, and mounted using Prolong Gold Antifade (Invitrogen). 
Immunofluorescence staining was performed as in (136). Images were taken using an 
LSM710 confocal microscope (Zeiss) The MRP5 antibody was a gift from Piet Borst 





For detection of MRP5, cells were lysed in SDS lysis buffer (2% SDS, 1% 
Triton X-100, 1 mM EDTA, 62.5 mM Tris-Cl pH 7.5) with protease inhibitors (1 mM 
phenylmethylsulfonyl fluoride, 4 mM benzamidine, 2 μg/ml leupeptin, and 1 μg/ml 
pepstatin), and sonicated twice. Cells were centrifuged at 14,000 x g for 15 min at 
4
o
C, and total protein concentration in the supernatants was measured using the 
Pierce BCA assay kit (Thermo Scientific). Unboiled samples were mixed with 
Laemmli sample buffer and 200 mM dithiothreitol (DTT), and 100 μg protein/lane 
were separated on 7% SDS-PAGE and transferred to a nitrocellulose membrane. The 
anti-MRP5 monoclonal antibody was used at a concentration of 1:200, goat anti-rat 
HRP-conjugated secondary was used at 1:30,000, and blots were developed in 
SuperWest Femto Chemiluminescent Substrate (Thermo Scientific). 





 MEFs were transfected with GolgiHRP expressed from 
the pShuttle-IRES-hrGFP-1 vector using the Lipofectamine transfection reagent 
(Invitrogen). The following day, cells were incubated in heme-depleted media 
(DMEM with 10% heme depleted FBS and 1% PSG) and 0.5 mM succinylacetone 
(SA). The following day, cells were switch to HD media + SA with the addition of 
1.5 or 2 μM heme. Cells were harvested a day later and lysed in 1% Triton X-100, 1 
mM EDTA, 62.5 mM Tris-Cl pH 7.5, with protease inhibitors (1 mM 
phenylmethylsulfonyl fluoride, 4 mM benzamidine, 2 μg/ml leupeptin, and 1 μg/ml 
pepstatin). Total protein concentration for each sample was measured using the 




each sample was measured as in (43). Each sample was normalized to the peroxidase 
activity in a corresponding empty vector control, as well as to total protein levels. 
Preparation of Red Blood Cells and In Vitro Erythrophagocytosis 
 Preparation of red blood cells (RBCs) and in vitro erythrophagocytosis (EP) 
was performed as in (43). Human blood was collected by finger prick using 
heparinized blood gas capillaries (Ram Scientific Inc.) and then opsonized. Blood 
was centrifuged at 800 rpm for 5 minutes and the serum was discarded. Plasma was 
washed with PBS three times. RBCs were incubated at 1:500 dilution with rabbit anti-
human RBC antibody (Cappel) at room temperature with gentle rocking for 1 hour. 
After incubation, RBCs were washed 3 times in PBS to remove excess unbound 
antibody. RBCs were counted and could be stored at 4°C for up to 4 days. 
Opsonization of carboxy-modified latex beads (CML beads) was carried out as 
follows: CML beads were incubated with bovine serum albumin (BSA, 1mg/ml in 
PBS) at 37°C for 1 hour. This was followed by cenfrigugation at 14,000 x g for 1 
hour and a wash in PBS. The beads were centrifuged again at 14,000xg, and the PBS 
wash was discarded. The BSA-coated beads were then incubated in the presence of a 
mouse anti-BSA antibody (Sigma, 10 μg/ml) at 37°C for 1 hour, followed by 3 
washed in PBS. 
EP was performed in the presence of HD media. Opsonized RBCs or latex 
beads were added to cultured BMDMs at the indicated RBC:BMDM ratio. 
Phagocytosis was allowed to occur for 60 min at 37°C, 5% CO2. Following EP, 
BMDMs were washed once with PBS, and incubated with hypotonic solution (140 




extracellular RBCs. Following 2 additional washes with PBS, BMDMs were cultured 
with HD media for the indicated periods of time. 
RNA Isolation, cDNA Synthesis and Quantitative RT-PCR 
RNA was isolated from BMDMs using the Nucleospin RNA II kit (Macherey 
Nagel). First strand cDNA was synthesized from 2 μg total RNA using the 
SuperScript III First-Strand Synthesis System (Invitrogen) and oligo(dT) primers. For 
qRT-PCR, primers used are listed in Appendix II. Real-time quantification of 
transcripts was performed in an iCycler iQ Real-Time PCR detection system (Bio-
Rad). Total reaction volume was 15 μl with 0.12U/ml Taq DNA polymerase, 40nM 
fluorescein (Invitrogen), 10 pmol of forward and reverse primer, and SYBR Green I 
Nucleic Acid Gel Stain (Invitrogen). Dissociation curve analysis and gel 
electrophoresis were used to monitor the quality of PCR products. In each 
experiments, biological samples were run in triplicates, and quantitative analysis for 
each sample was run in duplicate (n=6 per experiment). For each gene, results were 
normalized to the CT value of mGapdh. Relative fold changes in gene expression 
were assessed using the ΔΔCT method. Changes in gene expression were assessed 
relative to control samples of BMDM grown in HD media and harvested at each 





Preparation of Hemin Chloride 
 For all experiments, heme was added in the form of hemin chloride (Frontier 
Scientific, Logan, UT). Hemin chloride was prepared 10 mM stock by dissolving in 
0.3 M NH4OH. The pH of the solution was adjusted to 8.0 by addition of HCl. 
Microscopy 
 GFP, YFP, and ZnMP fluorescence in worms, yeast, or mammalian cells was 
imaged using a DMIRE2 epifluorescence microscope (Leica) connected to a Retiga 
1300 cooled mono 12-bit camera or using a laser scanning confocal microscope 
(LSM710) (Zeiss). 
Bioinformatics and Statistics 
 ClustalW and MEGA5 were used to generate a phylogenetic tree for the full 
length sequences of all human, mouse, zebrafish, and C. elegans MRP/ABCC 
proteins (137, 138). Membrane protein topologies were generated using TMHMM 
and drawn using TOPO2 (139, 140). All data are presented as mean ± the standard 
error of the mean. Statistical significance was determined using one-way or two-way 
ANOVA with Bonferroni post-tests (as indicated in figure legends) in GraphPad 









My days are in the yellow leaf; 
The flowers and fruits of Love are gone; 
The worm, the canker, and the grief 
Are mine alone! 
 
Lord Byron 




Hemes are metalloporphyrins used by nearly all organisms as protein 
cofactors for energy production, binding and sensing gases, and as an electron donor 
or acceptor for various redox reactions. While heme biosynthesis has been well-
characterized, the pathways for transporting heme between cells and within a cell 
remain poorly understood. C. elegans serves as a unique animal model for uncovering 
these pathways, as it is unable to synthesize its own heme. As a heme auxotroph, C. 
elegans is dependent on both maternally-derived heme for embryonic development, 
as well as heme acquired from the diet during larval growth (120). Heme is imported 
into the cytosol of the worm intestine via the conserved heme permease, HRG-1 and 
its paralog HRG-4 (40). The intercellular heme-trafficking protein, HRG-3, is 
secreted from the intestine and carries heme to developing embryos (77). HRG-2 is an 
extra-intestinal, heme-binding membrane protein that facilitates heme utilization in 




conditions, we postulated the existence an alternate mechanism for heme export from 
the intestine. 
 We previously identified mrp-5 as one of several regulators of heme 
homeostasis in C. elegans via an RNAi screen (142). Here we show that this 
candidate gene, a conserved ABC transporter, is transcriptionally heme responsive 
and regulates GFP expression in the heme sensor worm strain (IQ6011). RNAi 
depletion of mrp-5 results in embryonic lethality in the F1 generation, and deletion of 
mrp-5 results in larval growth arrest. Both these phenotypes can be rescued by the 
addition of excess heme to the diet. Regulation of mrp-5 is different than previously 
studied heme transporters in C. elegans, as it is expressed across a wide spectrum of 
heme concentrations. In the intestine, MRP-5 is found in basolateral sorting vesicles 
and on the basolateral plasma membrane. Knockdown of mrp-5 additionally results in 
the accumulation of a fluorescent heme analog in the worm intestine and upregulates 
extra-intestinal heme deprivation signals. While mrp-5 is expressed in multiple 
tissues, we show that loss of mrp-5 specifically from the intestine leads to altered 
heme homeostasis in the worm and the associated embryonic lethality. Taken 
together, these data indicate that mrp-5 is the intestinal heme effluxer in C. elegans. 
Results 
Identification of mrp-5 as a regulator of heme homeostasis in C. elegans 
 
 Our previous studies implicated HRG-3 in the directed trafficking of heme to 
extra-intestinal tissues, including embryos (Figure 3.1). However, hrg-3 mutant 














Figure 3.1: Current model of heme homeostasis in C. elegans.  
The heme permeases HRG-4, and HRG-1, which are localized to the apical plasma 
membrane and endolysosomal compartments, respectively, both import heme into the 
cytosol of intestinal cells. HRG-3 is secreted from the intestine for heme delivery to 





In fact, when worms are grown in the presence of >6 μM heme, hrg-3 mRNA is 
undetectable (77). Thus, HRG-3 serves as an inducible mechanism for redirecting 
heme stores only under heme-limiting conditions. These results would also predict 
that, in the absence of HRG-3, an alternate pathway exist in C. elegans. 
We postulated that membrane-bound heme transporters would be suitable 
candidates for regulating systemic heme homeostasis in the worm, and consequently 
impact the regulation of other heme-responsive genes. By individually depleting 288 
heme-responsive genes, which included 41 genes encoding transmembrane domain-
containing proteins, we uncovered mrp-5
2
 (WormBase accession number F14F4.5) as 
a potent regulator of the C. elegans transgenic heme sensor strain, IQ6011. The 
IQ6011 strain expresses GFP in the intestine from the heme-responsive hrg-1 
promoter; GFP levels in this strain are inversely correlated with heme levels in the 
worm (40, 143). As proof-of-principle, when the intestinal heme importer, hrg-4, is 
depleted in worms grown at low heme (≤20 μM), GFP is upregulated compared to 
vector control worms. Depletion of mrp-5 in IQ6011 by RNAi also resulted in 
significantly greater GFP levels compared to control RNAi, indicating that loss of 
mrp-5 results in the animal sensing less heme (Figure 3.2A and (142)). Importantly, 
this heme depletion signal could be rescued in a concentration-dependent manner by 
supplementation with dietary heme (Figure 3.2A). The increased GFP signal observed 
by knockdown of the intestinal heme importer, hrg-4, could be completely suppressed 
with 50 μM heme, while the mrp-5 RNAi signal persisted even at 500 μM, indicating
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 Throughout this text, worm genes will be written in the format mrp-5, and worm proteins will be 
written as MRP-5. Zebrafish genes will be written mrp5, and zebrafish proteins written as Mrp5. 
Mouse genes will be written as Mrp5, and proteins as Mrp5, while human genes will be written in the 
format MRP5 and human proteins as MRP5. When referring to a MRP5 proteins from all four species, 






Figure 3.2: mrp-5 is involved in heme homeostasis in C. elegans.  
Loss of mrp-5 results in a heme depletion signal that can be rescued by dietary heme. 
(A) GFP fluorescence (60-120 worms per treatment) quantified using COPAS 
BioSort in IQ6011 (Phrg-1::GFP::unc-54 3’ UTR; unc119(ed3); unc-119 rescue 
fragment) exposed to vector, hrg-4, or mrp-5 RNAi. ***P<0.001 when compared to 
vector control under the same conditions (two-way ANOVA, Bonferroni post-test). 
(B) Images of IQ6011 RNAi worms from (A) grown on RNAi bacteria supplemented 
with 50 μM heme. Scale bars, 50 μm. (C) Quantification of hrg-1 and mrp-5 mRNA 
by qRT-PCR. Relative fold changes were derived by normalizing the cycle threshold 
values to gpd-2 and then to the control heme level of 20 μM using ΔΔCT methods. 




a far more severe defect (Figure 3.2A and B). In addition, microarray analysis showed 
that mrp-5 is itself a heme responsive gene as its mRNA increased over 3-fold under 
low heme conditions (142). This result was confirmed by qRT-PCR studies showing 
that the mrp-5 transcript is upregulated about 5-fold in worms grown at 1.5 μM heme 
compared to worms grown at 20 μM heme (Figure 3.2C). Indeed, in silico analysis of 
the putative mrp-5 promoter revealed the presence of a canonical 23-base pair heme 
response element, which we have previously shown is necessary and sufficient to 
mediate heme dependent regulation of hrg-1 in the worm intestine (143).  
Although the C. elegans genome contains eight mrp genes, mrp-5 is the only 
mrp family member that significantly alters GFP expression in IQ6011 (Figure 3.3A),  
and is the sole mrp that is transcriptionally responsive to heme (142). An analysis of 
phenotypes associated with deletion of the eight mrp genes revealed that mrp-5 is the 
sole mrp that is lethal when deleted. As Flvcr1 has been shown to be a heme exporter 
in mammals, we asked whether putative homologs of this transporter regulated heme 
homeostasis in C. elegans (34, 35, 144). Systematically depleting each of the five 
Flvcr1 worm homologs had no significant effect on GFP levels in the heme sensor 
worm (Figure 3.3B) 
MRP-5 is essential for embryonic development and larval growth 
In worms, mrp-5 (multidrug resistance protein 5) encodes an ABC transporter 
of the MRP/ABCC family. The mrp-5 open reading frame is encoded on the reverse 
strand of the X chromosome (Figure 3.4A). The gene contains 20 exons, is 
transcribed as a 8066 nucleotide transcript, with 4284 nucleotides of coding sequence 






Figure 3.3: Loss of mrp-5, and no other mrp, results in a heme depletion signal in 
the heme sensor strain, IQ6011.  
(A) GFP fluorescence (60-120 worms per treatment) quantified from the hrg-1 
transcriptional fusion line (IQ6011) exposed to vector, or RNAi against an mrp gene 
at 25 μM heme. GFP was quantified using COPAS BioSort. ***P<0.001 when 
compared to vector control under the same conditions (one-way ANOVA, Bonferroni 
post-test). (B) RNAi of FLVCR1 homologs in C. elegans does not activate a heme 
depletion signal in IQ6011. GFP fluorescence in IQ6011 was measured as in Figures 
1B and 1C. ***P<0.001 when compared to vector control under the same conditions 






Figure 3.4: Gene structure and protein topology of mrp-5.  
(A) Detailed exonic structure of mrp-5, including the ok2067 deletion. Boxes indicate 
exons, with open boxes showing protein coding regions, and shaded boxes indicating 
untranslated regions. The region deleted in ok2067 is shown in black, with the start 
and end positions of the mutation in the spliced transcript indicated above the deleted 
region. (B) MRP-5 membrane topology showing an N-terminal membrane spanning 
domain (MSD1) consisting of six TMDs, followed by a cytosolic ATP binding 
cassette (ABC) domain, a second MSD (MSD2) and a second ABC domain. Residues 
deleted in the ok2067 mutant are shown in red. (C) Schematic of mutant MRP-5 
protein produced from mrp-5(ok2067) deletion allele. The deletion removes three 
transmembrane domains, causing the second ATP-binding cassette (ABC) domain to 





to include two membrane spanning domains (MSDs), each containing six 
transmembrane helices, and two intracellular ATP binding cassette (ABC) domains 
(Figure 3.4B) (145). Worms were analyzed for growth and developmental phenotypes 
after RNAi depletion of mrp-5. When synchronized larvae (P0) were fed mrp-5 RNAi 
bacteria, they showed no major developmental defects and were able to reach adult 
gravid stage and lay eggs. However, 80% of the F1 eggs laid by P0 worms failed to 
hatch, and the small number that did hatch arrested as L1 larvae (Figure 3.5A). This 
striking embryonic lethal phenotype could be rescued by supplementation of the 
bacterial food with exogenous heme; 95% of F1 progeny hatched and became adults 
in the presence of 500 μM heme. Together, these results indicate that mrp-5 is 
required for embryonic development in C. elegans. 
The strain VC1599 contains a deletion in mrp-5 (ok2067) spanning exons 14 
through 17 (Figure 3.4A and Figure 3.5A, top panel), but is genetically balanced by a 
marked chromosomal translocation as mrp-5 mutant worms are embryonic lethal 
(146). The mrp-5 (ok2067) deletion removes 176 amino acids, including three 
transmembrane helices. Consequently, the predicted topology of the mutant protein 
contains only nine transmembrane helices, resulting in a dysfunctional protein with 
the second ABC domain located on the exoplasmic side (Figure 3.4C). Although RT-
PCR and sequencing analysis reveals the presence of mrp-5 mRNA in mutant worms, 
depletion of mrp-5 by RNAi in the mrp-5(ok2067) mutants does not enhance or result 
in additional phenotypes suggesting that mrp-5(ok2067) is likely a null mutation 










Figure 3.5: Loss of mrp-5 results in embryonic lethality and larval arrest.  
(A) Dead progeny of vector control or mrp-5(RNAi) worms. ***P<0.001 when 
compared to vector control worms under identical conditions, n=3 (two-way 
ANOVA, Bonferroni post-test). (B) TOP: The C. elegans mrp-5 gene contains 20 
exons across 7 kb of the X chromosome. mrp-5 mutants harbor a 1.2 kb deletion 
(ok2067) spanning exons 14 through 17. BOTTOM: Wild-type and mrp-5 null brood 
mates were grown to gravid adult stage at 200 μM heme. Their F1 progeny were 
placed as synchronized L1 larvae on plates seeded with OP50 bacteria with or 
without 200 μM added heme. Representative images of F1 worms 4 days post-




We tested whether supplementary heme could rescue the embryonic lethality 
of mrp-5 mutants and found that when VC1599 worms were crossed to wild-type N2 
worms to eliminate the balancer, viable F2 homozygous mrp-5 mutant worms were 
obtained and easily propagated - but only when worms were grown on food 
supplemented with >200 μM heme. When grown on plates containing bacteria with 
no added heme, mrp-5(ok2067) homozygous mutant larva arrested at mid-larval 
stages, indicating that mrp-5 is required not just maternally, but also during larval 
development (Figure 3.5B, lower panel). We performed a growth curve to assess the 
amount of heme required to rescue the mrp-5(ok2067) mutant. Synchronized wild-
type and mutant worms (P0) were placed as L1 larvae on plates seeded with bacteria 
grown in the presence of increasing concentrations of heme and hatching of their F1 
progeny was counted. Some rescue was observed in worms grown at 50 μM, and full 
rescue was observed at 200 μM heme (Figure 3.6A). Brood size was counted in N2 
worms, mrp-5(ok2067) worms, and their wild-type brood mates under identical 
conditions. While mrp-5(ok2067) worms grown from the L1 stage at low heme did 
not reach adulthood and did not have progeny, the brood size of mrp-5(ok2067) 
worms grown in the presence of 200 μM heme was not significantly different than 
that of N2 or wild-type broodmare worms (Figure 3.6B).  
To determine if the rescue of mrp-5 lethality by dietary heme was due to the 
presence of redundant mechanisms for heme transport, we depleted FLVCR 
homologs in the mrp-5(ok2067) background. Only one, B0416.5, showed a 
significantly enhanced phenotype in the mrp-5 mutant worms when depleted 







Figure 3.6: Heme-dependent rescue of the mrp-5(ok2067) mutant.  
(A) Percent hatching in the progeny of mrp-5(ok2067) worms and wild-type brood 
mates grown on plates from L1 to gravid stage at indicated heme concentrations, n = 
2. (B) Total progeny of mrp-5(ok2067) worms and wild-type brood mates grown on 
plates from L1 to gravid stage at indicated heme concentrations; nd, not detected, ns, 
not significant. *P<0.05 when compared to N2 worms under identical conditions, n=5 




manner by exogenous heme and is likely unrelated to heme export from the intestine.  
C. elegans development requires intestinal MRP-5  
To determine the tissue-specific expression of mrp-5, a transcriptional reporter 
was generated using the putative promoter region of mrp-5 (3 kb upstream of the 
ATG start codon) fused to a GFP reporter. Pmrp-5::GFP was expressed at all 
developmental stages, with low levels in the hypodermis and in some neurons, and 
was consistently highly expressed in the intestine and pharynx (Figure 3.7A), 
confirming published intestinal and pharyngeal in silico gene expression analysis 
(147, 148). The expression pattern of mrp-5 was identical whether the transcriptional 
reporters was fused to the mrp-5 3’ untranslated region (UTR) or the generic unc-54 
3’ UTR (data not shown). We analyzed the expression pattern of this transgene grown 
at varying heme concentrations. GFP expression was observed in worms grown at 
both 1.5 and 50 μM heme, with no significant difference observed (Figure 3.7B). In 
fact, Pmrp-5::GFP is expressed in the presence of >500 μM heme (data not shown). 
To delineate the subcellular localization of MRP-5, GFP was fused to the C-
terminus of MRP-5 and expressed from the intestinal vha-6 promoter (149). In the 
polarized worm intestinal cells, Pvha-6::MRP-5::GFP localized to basolateral 
membranes (Figure 3.8A and B) and to intracellular membrane compartments, 
reminiscent of basolateral sorting vesicles (Figure 3.8C) (150). Similar localization 
was observed for MRP-5::GFP expressed from the endogenous mrp-5 promoter (not 
shown). We next determined if the transgene was capable of rescuing the embryonic 
lethal phenotype induced by mrp-5 deficiency. RNAi directed against the 3’ 





Figure 3.7: mrp-5 is expressed in multiple tissues in C. elegans.  
(A) GFP expression in IQ5051 (Pmrp-5::GFP::unc-54 3’UTR; unc-119(ed3); unc-119 
rescue fragment) as determined using confocal microscopy. mrp-5 is expressed in the 
hypodermis and some neurons, and at higher levels in the pharynx and intestine. P, 
pharynx, I, intestine, H, hypodermis, E, embryo. Scale bars, 20 μM. (B) mrp-5 
expression at different concentrations of heme. IQ5051 worms with the Pmrp-
5::GFP::unc-54 3’UTR construct were grown on plates seeded with bacteria grown 
in 1.5 μM or 50 μM heme for one generation. GFP signal was examined as a direct 
reporter for the activity of the mrp-5 promoter. Representative images of adult worms 










Figure 3.8: MRP-5 localizes to the basolateral membrane of the intestine.  
(A) Transgenic IQ5351 worms (Pvha-6::MRP-5:GFP::unc-54 3’UTR; unc-119(ed3); 
unc-119 rescue fragment) expressing an mrp-5 translational reporter were imaged by 
confocal microscopy. Dotted lines indicate apical membrane, dashed lines indicate 
basolateral membrane, and arrowheads indicate lateral membranes between adjacent 
intestinal cells. Scale bar, 50 μM. (B) Images of a worm expressing the MRP-5::GFP 
translational fusion protein. Images were taken at two different planes along the 
dorsal-ventral axis. Localization of MRP-5::GFP to lateral membranes of adjacent 
intestinal cells can be seen in (a), while localization of MRP-5::GFP to the basolateral 
membranes and not the apical membrane surrounding the intestinal lumen can be seen 
in (b). The anterior of the animal is to the left. Scale bar, 50 μM. (C) Magnified image 
of MRP-5::GFP localization to basolateral sorting vesicles. Image is taken in the 
same plane as (a) in Figure 3.8B. Arrowhead indicates lateral membranes of adjacent 








embryonic lethality phenotype (Figure 3.9A), whereas the MRP-5::GFP transgene, 
which is expressed with the generic unc-54 3’ UTR, was left intact, as confirmed 
visually by GFP fluorescence (not shown). RNAi against the mrp-5 3’ UTR in lines 
expressing MRP-5::GFP resulted in no embryonic lethality in MRP-5::GFP 
transgenic worms, indicating that MRP-5::GFP is a functional protein that can rescue 
the mrp-5 RNAi phenotype (Figure 3.9A). 
As MRP-5 is expressed in multiple tissues, it is conceivable that mrp-5 
depletion in any or all of the tissues may contribute to the embryonic lethal phenotype 
of mrp-5 mutant worms. To address the contribution of each tissue to the mrp-5 
phenotype, we utilized tissue-specific RNAi worm strains. Worms carrying the rde-1 
mutation are resistant to RNAi; ectopic expression of rde-1 from a tissue-specific 
promoter in the rde-1 mutant background results in RNAi only in that tissue (151). 
We depleted mrp-5 in the VP303 (rde-1 rescue from the intestinal nhx-2 promoter), 
WM118 (rde-1 rescue from the muscle myo-3 promoter), and NR222 (rde-1 rescue 
from the hypodermal lin-26 promoter) transgenic worm lines. Depletion of mrp-5 in 
the intestine fully recapitulated the F1 embryonic lethality of whole animal RNAi, 
while depletion of mrp-5 either in the hypodermis or muscle had no effect on F1 
viability (Figure 3.9B). The lethality caused by RNAi in the VP303 strain could be 
rescued by supplementation with 500 μM heme in the diet. Thus, the lethality of mrp-
5 mutants can be attributed to loss of functional MRP-5 specifically in the intestine, 
even though mrp-5 is expressed in extra-intestinal tissues. This is further supported 





Figure 3.9: Loss of mrp-5 specifically in the intestine causes embryonic lethality.  
(A) Intestinal RNAi of mrp-5 recapitulates the embryonic lethality of whole animal 
mrp-5 RNAi. Wild type N2 worms and the tissue specific RNAi strains were grown 
on RNAi plates with no added heme.  Int, intestinal RNAi, Mus, muscle RNAi, Hyp, 
hypodermal RNAi, n=2. See the text and Appendix I for further strain information. 
(B) The MRP-5::GFP fusion gene can rescue the embryonic lethality of mrp-5 RNAi. 
RNAi targeting the mrp-5 ORF causes embryonic lethality in both wild type N2 and 
transgenic worms. RNAi against the mrp-5 3’ UTR results in a less severe embryonic 
lethal phenotype in N2 worms, but this lethality is significantly rescued by expression 
of the MRP-5::GFP transgene from either the mrp-5 or the intestinal vha-6 promoter. 
***P<0.001 when compared to wild type N2 worms under identical conditions, n=3 








(Pvha-6::MRP-GFP) is capable of rescuing the hatching phenotype associated with 
depletion of endogenous mrp-5 (Figure 3.9A). 
MRP-5 is an intestinal heme exporter 
As MRP-5 is a member of the ABCC/MRP transporter family, members of 
which function as exporters of lipophilic and organic compounds (114, 152), we 
examined whether MRP-5 was involved in heme transport in C. elegans. In order to 
do this, we examined the response of mrp-5(RNAi) worms to various heme analogs. 
We have previously shown that worms in which mrp-5 was RNAi depleted are 
resistant to the toxic heme analog, gallium protoporphyrin IX (GaPPIX), indicating 
that heme analogs entered the intestine but were poorly accessible to extra-intestinal 
cells (142). Additionally, worms in which mrp-5 had been depleted showed 
significantly greater accumulation of zinc mesoporphyrin IX (ZnMP), a fluorescent 
heme analog, in the intestine compared to control worms (Figure 3.10A and B). 
Notably, VC1599 worms, which are heterozygous for mrp-5, exhibited 
haploinsufficiency phenotypes. They not only accumulated ZnMP in the intestine, but 
were also resistant to GaPPIX (Figure 3.11A and B).  
To evaluate the heme status in an extra-intestinal tissue when mrp-5 is 
depleted, we utilized Phrg-2::HRG-2::YFP transgenic worms. The hrg-2 promoter is 
active only in the hypodermis and Phrg-2::HRG-2::YFP is induced in the hypodermis 
when heme levels are limiting in that tissue (141). Depletion of mrp-5 resulted in a 
striking increase in HRG-2::YFP levels and its expression was not fully suppressed 
until worms were fed 500 μM heme (Figure 3.12A and B). By contrast, worms in 












Figure 3.10 Loss of mrp-5 leads to intestinal accumulation of a heme analog.  
Zinc mesoporphyrin (ZnMP) staining in worms fed vector control or mrp-5(RNAi) 
bacteria. (A) Worms were exposed to RNAi from L1 to L4 larval stages, pulsed with 
60 μM ZnMP for 3 hr, and imaged using confocal microscopy. Scale bars, 20 μm. (B) 
Quantification of ZnMP staining (mean ± SEM of 10 worms) in worms from (A). 









Figure 3.11: VC1599 (mrp-5/+) worms exhibit haploinsufficiency phenotypes.  
(A) ZnMP staining in N2 control or VC1599 (mrp-5/+) worms. Worms were exposed 
to RNAi from L1 to L4 stage, pulsed with 60 μM ZnMP for 3 hr, and imaged on an 
inverted microscope. Representative images of intestinal granules containing ZnMP 
in control and mutant worms are shown. Scale bars, 20 μm (B) Resistance to a toxic 
heme analog, gallium protoporphyrin IX (GaPPIX), was measured in wild-type N2 
and VC1599 (mrp-5/+) worms. Resistance was assessed after L4 worms were 
exposed to varying concentrations of GaPPIX for 48 hours. Worms were considered 
dead when unresponsive to a physical stimulus. Each data point represents the mean ± 
SEM of three separate experiments and is depicted as percentage of survival 
compared to control plates with no GaPPIX. **P<0.01 when compared to wild-type 





Figure 3.12: Loss of mrp-5 results in an extraintestinal heme depletion signal.  
(A) LEFT: YFP fluorescence (60-100 worms per treatment) quantified using COPAS 
BioSort in the hrg-2 translational fusion line, IQ8122 (Phrg-2::HRG-2:YFP::hrg-2 3’ 
UTR, unc-119(ed3); unc-119 rescue fragment) exposed to vector, hrg-4, or mrp-5 
RNAi at varying heme concentrations. ***P<0.001, **P<0.01 when compared to 
vector control worms (two-way ANOVA, Bonferroni post-test). RIGHT: 
Representative images of worms grown at 1 μM heme from left panel. Scale bars, 100 
μm. (B) Expression of GFP in IQ6011 L1 larvae. P0 worms were grown in liquid at 
the indicated heme concentrations, and their synchronized progeny were placed as L1 
worms on vector or mrp-5 RNAi plates. These worms were grown to gravid stage, 









Phrg-2::HRG-2::YFP, indicating that loss of this particular transporter does not result 
in limiting heme levels in the hypodermis (Figure 3.12A, left panel). 
As heme levels in C. elegans embryos and newly hatched larvae are 
intrinsically linked to maternal heme status, we analyzed GFP levels in the progeny of 
IQ6011 worms. These larvae are predicted to behave like extra-intestinal tissues and 
upregulate depletion signals when heme is limiting. IQ6011 worms (P0) were grown 
in liquid media at the indicated heme concentrations, and their synchronized progeny 
were placed as L1 worms on vector or mrp-5 RNAi plates. These worms were grown 
to gravid stage, and GFP fluorescence was analyzed in their progeny (F2) at the L1 
stage. Regardless of the heme concentration at which the P0 or F1 worms were grown, 
F2 worms that were the progeny of mrp5(RNAi) worms showed increased GFP 
compared to vector control worms (Figure 3.12B). These results, taken with the 
embryonic lethality associated with mrp5 RNAi, indicate that worms lacking mrp-5 
are unable to deliver adequate heme to extra-intestinal targets – namely developing 
embryos. Taken together, these results provide strong evidence that MRP-5 is the 
major intestinal heme exporter. 
HRG-3 overexpression cannot rescue MRP-5 loss-of-function phenotypes 
We next determined whether MRP-5 deficiency phenotypes could be 
overcome by expressing HRG-3, the intercellular heme delivery protein, from the 
intestine. Notably, loss of mrp-5 in a wild-type background suppresses hrg-3 
expression (Figure 3.13A). Thus, it is not surprising that hrg-3 is unable to rescue 
heme delivery to extra-intestinal tissues in the absence of mrp-5. We next determined 





Figure 3.13: Ectopic expression of hrg-3 cannot rescue mrp-5-associated 
lethality.  
(A) GFP fluorescence (60-100 worms per treatment) quantified using COPAS 
BioSort in the hrg-3 transcriptional fusion line, IQ8031 (Phrg-3::GFP::hrg-3 3’ UTR, 
unc-119(ed3); unc-119 rescue fragment) exposed to vector, hrg-4, or mrp-5 RNAi at 
varying heme concentrations. *P<0.05 when compared to vector control worms (two-
way ANOVA, Bonferroni post-test). (B) Ectopic expression of hrg-3 does not rescue 
the embryonic lethality of whole animal mrp-5 RNAi. Experiment was performed 
using wild-type N2 worms and worms ectopically expressing HRG-3 and GFP 
separated by the SL2 intercistronic sequence (hrg-3(tm2468); Pvha-6::HRG-
3::ICS::GFP, unc-119(ed3); unc-119 rescue fragment) grown on RNAi plates with 
no added heme. (C) RNAi depletion of mrp-5 does not inhibit the secretion of hrg-3 
from the intestine. Transgenic worms containing the Phrg-3::HRG-3::mCherry 
translational fusion were fed vector control or mrp-5 RNAi bacteria from L1 to L4 
stages. HRG-3::mCherry in extraintestinal cells (coelomocytes) was imaged on an 









mrp-5 lethality. Ectopic expression of hrg-3 from the intestinal vha-6 promoter was 
unable to rescue the embryonic lethality of mrp-5 RNAi (Figure 3.13B). This was not 
due to impaired secretion of HRG-3 from the intestine, as HRG-3::mCherry still 
accumulated in the extraintestinal coelomocytes when mrp-5 was depleted by RNAi  
(Figure 3.13C). 
Discussion 
The nematode C. elegans is unable to synthesize heme and is therefore 
dependent on a network of heme sensing, trafficking, and transport molecules to 
import environmental heme into the intestine and then export this heme to different 
tissues and subcellular compartments. We have previously shown that a network of 
heme importers regulates heme entry into the intestine, and that a heme chaperone 
delivers this essential nutrient to extra-intestinal tissues under heme-limiting 
conditions (40, 41, 77). However, a constitutive mechanism for heme export from the 
intestine remained elusive. 
In the current study, we show that MRP-5 plays an essential role in C. elegans 
heme homeostasis. Our conclusions about MRP-5 function are supported by the 
following findings: 1) targeted mrp-5 deficiency in the intestine causes embryonic 
lethality; 2) MRP-5 primarily localizes to the basolateral plasma membrane and 
MRP-5 deficiency results in ZnMP accumulation in the worm intestine; 3) mrp-5 is 
expressed during all developmental stages, and over a wide range of heme 
concentrations; 4) loss of mrp-5 activates a number of heme deficiency signals in the 
worm. Altogether, these results suggest that MRP-5 is the intestinal heme exporter in 




In our model (Figure 3.14), HRG-4 imports heme into the intestinal cytosol, 
where it can be exported to extra-intestinal targets or stored in endocytic 
vesicles.HRG-1 mobilizes heme from these storage vesicles when necessary. 
Presumably, cytosolic heme in the intestine is available for export by MRP-5, either 
directly into the pseudocoelom or into secretory vesicles, or both. HRG-3 is secreted 
from the intestine to escort heme to other tissues, and possibly acquires its heme from 
MRP-5. Mechanisms for heme uptake by other tissues remain unknown. 
 It is useful to compare the transcriptional regulation and phenotypes of mrp-5 
with that of the other hrgs. While hrg-1, hrg-4, and hrg-3 are only upregulated at <20 
μM heme, an mrp-5 transcriptional reporter is expressed even when worms are grown 
at >500 μM heme. While hrg-1, hrg-4, and hrg-3 are upregulated 20- to 400-fold in 
response to low heme, mrp-5 is upregulated 3- to 5-fold maximally. We can infer that 
only small changes in the regulation of mrp-5 are required to adjust to major changes 
in available dietary heme. This is also apparent from the haploinsufficiency 
phenotypes in the VC1599 (mrp-5/+) strain, demonstrating that relatively minor 
changes in mrp-5 expression result in observable physiological consequences in the 
worm. Additionally, loss of hrg-1, hrg-4, or hrg-3 individually results in no apparent 
phenotypes until worms are nutritionally deprived of heme. By contrast, loss of mrp-5 
results in crippling embryonic lethality and larval arrest that can only be rescued with 
very high concentrations of heme. Thus, while hrg-1, hrg-4, and hrg-3 cooperate to 
form an emergency response to heme starvation, mrp-5 functions as a part of the 
basal heme transport machinery. While redundancy exists among the paralogs of 








Figure 3.14: Proposed model of heme transport pathways in C. elegans.  
In C. elegans, mrp-5 is expressed at all developmental stages, mainly in the intestine. 
After heme is imported into the cytosol of intestinal cells, MRP-5, which localizes to 
the basolateral membrane, can export heme to extra-intestinal tissues. As MRP-5 also 
localizes to basolateral sorting vesicles, it may also be responsible for delivery of 
heme to HRG-3, and other hemoproteins in the secretory pathway. Heme uptake 




indicates that there are likely no alternate mechanisms for heme efflux from the 
intestine. 
Interestingly, loss of mrp-5 expression negatively regulates an hrg-3 
promoter-driven transcriptional reporter. One explanation for this observation is that 
the hrg-3 promoter is regulated exclusively by heme located within the intestinal 
compartment. According to our model, depletion of mrp-5 would result in heme 
accumulation in the intestine, repressing hrg-3 expression. This also explains why 
loss of mrp-5 is lethal despite the presence of HRG-3-mediated heme export from the 
intestine. Another, not mutually exclusive, explanation is that MRP-5 is responsible 
for delivering heme to apoHRG-3 as it progresses through the secretory pathway. In 
the absence of MRP-5, HRG-3 is unable to acquire heme and deliver it to other 
tissues. In support of this hypothesis, we showed that even constitutive 
overexpression of HRG-3 was unable to rescue the embryonic lethality associated 
with mrp-5 RNAi. 
An unanticipated consequence of MRP-5 deficiency in worms is the apparent 
uncoupling of heme levels in the intestine and heme levels in extra-intestinal tissues. 
In the absence of an intestinal heme exporter, it would be expected that heme will 
accumulate in the intestine and extra-intestinal tissues will be heme-deprived, as seen 
when mrp-5 is depleted in the HRG-2::YFP reporter strain. However, depletion of 
mrp-5 also results in robust expression of the Phrg-1::GFP intestinal heme reporter, 
and this occurs when heme is accumulating within the intestine, a condition when 
such transporters are not normally expressed. If the hrg-1 promoter was solely 




It is possible that mrp-5 depletion causes compartmentalization of accumulated heme 
in the intestine such that this heme can no longer be detected by the hrg-1 promoter. 
However, another plausible interpretation of this paradox is that intestinal heme levels 
are integrated with and regulated by heme-dependent signals from extra-intestinal 
tissues. That low extra-intestinal heme levels can activate a depletion signal within a 
heme-loaded intestine implies the existence of a network for communicating heme 
status between extra-intestinal tissues and their sole source of heme, the intestine. It is 
plausible that cellular heme levels in C. elegans are not solely regulated by internal 
heme content, but also by distally located proteins which signal systemic heme 
requirements to an inter-tissue heme trafficking network. 
A number of questions remain. First, it is unlikely that cytotoxic heme is 
floating freely in the cellular milieu of the intestine. Is there an intestinal chaperone 
responsible for sequestering and ferrying heme in these cells? Does this chaperone 
interact with the heme importers, HRG-1 and HRG-4, or the heme exporter, MRP-5, 
or both? We predict that this protein will be constitutively expressed, like mrp-5, as it 
is required for basal heme trafficking; however we cannot rule out the existence of 
multiple chaperones, as observed for copper trafficking - each directing a specific 
pathway (153), some of which may be regulated by heme levels. 
Second, MRP-5 is found in recycling vesicles targeted to the basolateral 
membrane. Is MRP-5 responsible for transporting heme from the cytosol into the 
intestinal secretory pathway, possibly for insertion into heme-binding proteins located 
in subcellular organelles? As previously mentioned, HRG-3 expression cannot rescue 




delivering sufficient heme to developing embryos, but we alternatively hypothesize 
that heme-loading into HRG-3 may require MRP-5. An alternative explanation could 
be that RNAi of mrp-5 somehow downregulates the currently unknown receptor for 
HRG-3 in worm embryos. 
Third, how are high concentrations of dietary heme able to rescue lethality 
associated with loss of mrp-5? We showed that depletion of FLVCR homologs in 
mrp-5(ok2067) worms does not result in a stronger phenotype, indicating that these 
proteins are not the alternate low-affinity heme exporters delivering heme to extra-
intestinal tissues in the absence of MRP-5. It is worth noting, however, that this 
experiment does not rule out the presence of other low-affinity transporters that can 
compensate for the loss of mrp-5, or the possibility that at such high dietary 
concentrations, heme, which can intercalate into membrane lipids, is traversing the 
membrane without the assistance of a transporter.  
Last, evidence from this study indicates that MRP-5 is found in tissues outside 
the intestine – namely the pharynx. It is possible that MRP-5 protects these tissues 
from the buildup of toxic heme, or perhaps plays a role in targeting heme to a specific 
subcellular compartment, such as the ER or Golgi apparatus? Further subcellular 
localization studies and analysis of tissue-specific knockdown mutants will be critical 









Who goes there? Hankering, gross, mystical, nude, 
How is it I extract strength from the beef I eat? 
 
Walt Whitman 




 While C. elegans is a heme auxotroph, and thus necessarily relies on elaborate 
heme trafficking mechanisms, it has been assumed that organisms capable of 
synthesizing heme do not similarly mobilize heme. However, there is evidence for 
conserved heme transport pathways. We have previously showed that while C. 
elegans and human HRG1 only share about 20% sequence identity, they both bind 
and transport heme (41). Furthermore, depletion of zebrafish hrg1 using morpholino 
knockdown results in severe anemia and morphological defects that can be rescued by 
co-injection with C. elegans hrg-1 (40). To determine if heme transport by MRP-5 is 
conserved in other species, we took advantage of a heme synthesis-deficient yeast 
strain. The hem1∆ strain lacks δ-aminolevulinic acid (ALA) synthase; as yeast do not 
possess a robust plasma membrane heme import system, the hem1∆ strain is 
incapable of growth in the absence of ALA or high levels of exogenous heme. We 




rescue the growth of this strain in the presence of low heme, indicating that they are 
bone fide heme transporters.  
 Here we show that MRP5 proteins, which are conserved among metazoans, 
are broadly capable of transporting heme. Studies in zebrafish show that, similar to 
hrg1, loss of mrp5 results in severe anemia. Expression of this heme effluxer 
decreases growth of hem1∆ yeast grown on either heme or ALA, indicating that both 
exogenous heme and endogenously synthesized heme are capable of being 
transported by MRP5. We additionally use heme reporter assays to determine that 
MRP5, which localizes to intracellular membranes, exports heme into the secretory 
pathway, and as such decreases cytosolic heme levels in these yeast. Our results 
imply that regulation of heme homeostasis by MRP5 is highly conserved among 
metazoans. 
Results 
MRP5 is conserved in metazoans 
Vertebrate ABCC5/MRP5 is 39% identical to worm MRP-5 with similar 
overall membrane topology (Table 4.1). Within the ABCC/MRP family, the lack of 
an additional amino-terminal MSD (called MSD0) places ABCC5/MRP5 in a distinct 
group containing the ABCC4/MRP4, ABCC7 (CFTR), and ABCC12/MRP9 proteins 
(Figure 4.1, blue box) (154). Although C. elegans contains a single mrp-5, the gene 
has undergone a duplication event and two MRP5 paralogs are found in most 
vertebrates (Figure 4.1, red boxes). Interestingly, the human genome contains three 


















































       
Mouse 
(NP_038818.2) 
95.1       
Rat 
(NP_446376.1) 
94.8 97.8      
Chicken 
(XP_004943449.1) 
89.1 87.2 87.3     
Xenopus 
(XP_004914448.1) 
84.2 83.4 83.9 87.0    
Zebrafish 
(NP_001182542.1) 
73.9 73.2 73.6 74.3 76.3   
C. elegans 
(NP_510479.1) 
39.0 38.9 39.3 39.8 39.4 39.0  
Asian Rice 
(NP_001046583.1) 






Figure 4.1: Phylogenetic analysis of MRP and ABCC proteins.  
Phylogenetic tree of the MRP/ABCC family members in C. elegans (Ce), zebrafish 
(Zf), mice (m), and humans (h). Protein sequences were aligned using ClustalW and a 
phylogenetic tree was generated using the Neighbor-Joining method in MEGA5. The 
tree is drawn to scale, with branch lengths in the same units as those of the 
evolutionary distances used to infer the phylogenetic tree. The evolutionary distances 
are in the units of the number of amino acid substitutions per site. C. elegans mrp 
proteins are boxed in red, ABCC/MRP proteins lacking the N-terminal MSD0 domain 








ABCC12/MRP9 are located in tandem on chromosome 16 (155). Orthologs of 
ABCC11/MRP8 can be found in other eutherians, including primates, dogs, and cows, 
but are not found in rodent genomes. In all analyzed vertebrate species, the closest 
homolog of C. elegans mrp-5 is the vertebrate ABCC5/MRP5. 
Previous studies with HRG-1 have shown that even though zebrafish and 
worm HRG-1 are only ~20% identical, they both function as heme transporters (40). 
Because zebrafish embryos provide a vertebrate animal model to interrogate 
hematological changes as a function of aberrant heme homeostasis (156), we 
analyzed the expression and function of mrp5/abcc5 in zebrafish. Whole mount in 
situ hybridization revealed that mrp5/abcc5 is widely expressed throughout the 
embryo, with the greatest expression in the developing central nervous system 
(Appendix IV and Appendix V, A). 
To knockdown mrp5/abcc5, we injected fish embryos with morpholinos (MO) 
specifically targeted against the ATG start codon of mrp5/abcc5 (MO
mrp5
) mRNA. 
Embryos injected with MO
mrp5
 showed severe anemia with very few o-dianisidine-
positive red blood cells (RBCs) compared to embryos injected with control MO 
(Appendix V, B and E). MO
mrp5
 morphants also exhibited developmental 
malformations including body axis curvature defects and enlarged hearts. To quantify 
the severe anemia phenotype, we analyzed levels of globin-expressing RBCs in the 
morphant fish. Transgenic zebrafish expressing GFP from the globin locus control 
region (LCR-GFP) were injected with control and mrp5 morpholinos, and morphant 
blood was analyzed two days post-fertilization for GFP expression. Fish injected with 
MO
mrp5 




fish (Appendix V, C). Correspondingly, gata1, a transcription factor required for 
primitive erythropoiesis (157) was robustly expressed in wild-type and control MO 
embryos, but little or no gata1 staining was observed in MO
mrp5
 morphants 
(Appendix V, D). The MO
mrp5
 anemia was indeed due to Mrp5/Abcc5 deficiency, as 
co-injecting zebrafish with cRNA encoding Mrp5/Abcc5 significantly corrected the 
anemia phenotype (Appendix V, E). Taken together, these data indicate that mrp5 is 
critical for zebrafish erythropoiesis, and that MRP5 regulation of systemic heme 
homeostasis is likely conserved from worms to vertebrates. 
MRP5 expression alters heme homeostasis in a heterologous system 
To determine whether MRP5 likely transports heme, we exploited previously 
established assays in yeast and mammalian cells. Saccharomyces cerevisiae hem1∆ 
mutants are unable to synthesize ALA, a precursor for heme synthesis, and grow 
poorly even in the presence of exogenous heme due to an inefficient heme uptake 
system (126, 158). This inadequate growth of hem1Δ can be greatly improved by 
either expression of a heme importer in the presence of heme or supplementation of 
ALA to the growth medium (41). When hem1Δ yeast express the C. elegans heme 
importers HRG-4 (CeHRG-4) or HRG-1 (CeHRG-1), their growth is increased 
compared to control yeast grown on heme-supplemented plates (Figure 4.2). When 
hem1Δ yeast express the yeast heme exporter, Pug1p (PUG1), their growth is reduced 
compared to control yeast on heme plates. Similarly, the growth of hem1Δ yeast 
expressing C. elegans MRP5 (CeMRP-5) or human MRP5 (both hMRP5 and C 
terminal tagged hMRP5 HA) is decreased, both in the presence of heme and in the 





Figure 4.2: Expression of MRP5 inhibits growth of a heme synthesis-deficient 
yeast strain.  
The hem1∆ yeast strain was transformed with indicated constructs and grown 
overnight in SC medium without ALA and spotted in serial dilutions on 2% raffinose 
SC (-Ura, +0.4% galactose) plates supplemented with indicated concentrations of 








zebrafish Mrp5 inhibited growth of hem1Δ yeast on heme-containing plates as well 
(Appendix VI). 
In order to quantify the ability of MRP5 to inhibit the growth of hem1Δ yeast, 
we grew yeast in the liquid culture and assayed yeast growth by measuring OD600 
over time. Uninduced yeast showed no significant difference in growth (Figure 4.3A, 
left panel). Upon induction with galactose, yeast expressing CeHRG-1 and CeHRG-4 
show significantly improved growth in medium supplemented with 0.5 μM heme 
when compared to control yeast (Figure 4.3B) (41). However, yeast expressing C. 
elegans MRP-5 or human MRP5 showed significantly reduced growth. The reduced 
growth of yeast expressing CeMRP-5 or hMRP5 was not due to cell toxicity 
associated with overexpression of a large polytopic membrane protein, as growth was 
restored when cells were co-transformed with the heme importer CeHRG-4 (Figure 
4.3B, bottom three rows).  
Yeast are capable of using sugar-based carbon sources such as galactose or 
raffinose for a mixture of aerobic and anaerobic respiration (159). Thus under heme 
deprivation conditions, yeast growing in the presence of a sugar-based carbon source 
can alternatively derive energy via fermentation, which is less heme-dependent than 
aerobic respiration. To further exacerbate the MRP5-dependent growth phenotype in 
hem1Δ yeast, we grew yeast expressing these putative heme transporters in the 
presence of glycerol and lactate, which yeast can utilize exclusively for aerobic 
respiration. While yeast expressing CeHRG-4 grew in the spot growth assay, neither 
control yeast nor yeast expressing PUG1, CeMRP-5, or hMRP5 were capable of 





Figure 4.3: Expression of MRP5 inhibits growth in a heme-dependent manner.  
(A) The hem1∆ yeast strain was transformed with indicated vectors, grown for 12 
hours in SC medium without added heme or ALA, and then grown in 2% raffinose 
SC (-Ura, +0.4% galactose) medium for 24 hours under the indicated conditions. 
Yeast growth was assessed by measuring OD600. LEFT: Uninduced yeast (+0.4% 
glucose) which did not express the transgenes showed no difference in growth after 
24 hours in the presence of 250 μM ALA. RIGHT: Induced yeast (+0.4% galactose) 
expressing heme importers HRG-1 and HRG-4 grow significantly better than control 
yeast. Yeast expressing MRP-5 grow significantly worse. ***P<0.001 compared to 
vector control after 24 hours, n=3 (two-way ANOVA, Bonferroni post-test). (B) The 
hem1∆ yeast strain was transformed with the indicated constructs, grown overnight 
without added heme or ALA and spotted in serial dilutions on 2% raffinose SC (-Ura, 
+0.4% galactose) plates supplemented with 0.5 μM heme. Plates were incubated at 
30°C for 72 h before imaging. (C) The hem1∆ yeast strain was transformed, grown 
overnight without added heme or ALA and spotted in serial dilutions on SC (-Ura, 
glycerol, lactate) plates supplemented with 5 μM heme. Plates were incubated for 3 








the three heme exporters was dominant over that of the heme importer (Figure 4.3C)  
Taken together, these results indicate that MRP5 has a conserved ability to regulate 
cellular heme homeostasis. 
MRP5 is a conserved heme transporter 
To assess whether MRP5 expression could alter intracellular heme levels in 
the yeast, we measured the activity of β-galactosidase derived from the lacZ reporter 
under control of the cytochrome c (CYC1) promoter. This promoter is activated by 
Hap1, a transcription factor positively regulated by cytosolic heme levels (160). Thus, 
in this assay, levels of β-galactosidase activity reflect the availability of heme in the 
cytosol to activate the CYC1 promoter. As proof of principle, yeast expressing Pug1p, 
a yeast heme effluxer, show decreased β-galactosidase activity. Supporting the 
hypothesis that they are heme transporters, both CeMRP-5 and hMRP5 showed 
decreased β-galactosidase activity when assayed in this system (Figure 4.4A, left 
panels). This result was consistent with the poor growth phenotype in the spot assay. 
This result was also reproducible in yeast grown in the presence of ALA, indicating 
that expression of MRP5 can also affect availability of endogenously synthesized 
heme (Figure 4.4A, right panels). Interestingly, yeast expressing MRP5 showed lower 
β-galactosidase activity than cells expressing PUG1 (126).  
To evaluate heme availability in the yeast secretory compartment, we 
measured the activity of a heme-dependent enzyme (ferric reductase) as an indicator 
of intracellular heme concentrations (126). In yeast, ferric reductase (Fre1p) acquires 
a heme cofactor needed for enzymatic activity in the secretory pathway before being 





Figure 4.4: Ectopic expression of MRP5 in yeast alters heme availability in the 
cytosol and the secretory pathway.  
(A) Heme-dependent β-galactosidase activity. The hem1∆ yeast strain was 
transformed with pCYC1-LacZ, as well as empty vector, ScPUG1, CeMRP-5, or 
hMRP5 and grown with the indicated amount of heme or ALA. Cell lysates were then 
analyzed for β-galactosidase activity, normalized to vector. ***P<0.001, **P<0.01, 
*P<0.05 when compared to yeast expressing empty vector under identical conditions, 
n=2 (one-way ANOVA, Bonferroni post-test). (B) Heme-dependent ferric reductase 
activity. The hem1Δfre1Δfre2ΔPGK1-FRE1 yeast strain was transformed with 
indicated vectors and grown with the indicated amount of heme or ALA. Ferric 
reductase activity from whole cells was analyzed. **P<0.01, *P<0.05 when compared 









in a hem1∆fre1∆fre2∆MET3-FRE1 yeast strain. In this strain, the endogenous genes 
for FRE1 and FRE2, which are regulated by the presence of iron and copper, are 
deleted, and Fre1p is constitutively expressed from the MET3 promoter. Thus, in this 
strain, ferric reductase activity is indicative of heme availability in the secretory 
pathway. While Pug1p expression had minimal effect at these heme and ALA 
concentrations, yeast expressing CeMRP-5 or hMRP5 showed significantly greater 
ferric reductase activity in the presence of either heme or ALA, indicating greater 
heme availability in the secretory pathway (Figure 4.4B). 
Although most MRP transporters expressed in yeast localize to the vacuolar 
membranes (162), indirect immunofluorescence microscopy localized CeMRP-5 and 
hMRP5 primarily to intracellular compartments that are distinct from the plasma 
membrane and the vacuole (Figure 4.5A and B). Taken together, these results indicate 
that when expressed in yeast, MRP5 proteins are capable of exporting heme from the 
cytosol into intracellular organelles for delivery to hemoproteins such as Fre1p. 
Discussion 
Genetic evidence indicated that C. elegans MRP-5 functions as a heme 
effluxer. As MRP5 is conserved in metazoans, we sought to determine if its ability to 
regulate heme homeostasis is conserved in other species. The current study showed 
that mrp5 is widely expressed early during zebrafish development and that loss of 
Mrp5 leads to severe anemia and developmental defects. We also sought to determine 
if C. elegans MRP-5 was capable of transporting heme, and if this ability was 
conserved in other MRP5 family members. Indeed, C. elegans MRP-5, zebrafish 








Figure 4.5: MRP5 localizes to intracellular membranes in yeast.  
The hem1Δ yeast strain expressing (A) CeHRG-4-flag or CeMRP-5-flag or (B) 
CeHRG-4-HA or hMRP5-HA was subjected to indirect immunofluorescence 
microscopy using anti-flag or anti-HA antibodies and imaged by confocal 




analyzed the effect of MRP5 expression on subcellular heme reporters in this yeast 
strain, and further showed that both C. elegans MRP-5 and human MRP5 reduce 
heme availability in the cytosol with a concomitant increase in heme availability in 
the secretory pathway. When expressed in yeast, both worm and human MRP5 
localize to intracellular membranes which are distinct from the vacuole or plasma 
membrane. Taking these data together, we conclude that MRP5 proteins are capable 
of effluxing heme from the cytosol into the secretory pathway in yeast. 
Results from our experiments in zebrafish indicate that MRP5 proteins play a 
conserved role in organismal heme homeostasis. Morpholino knockdown experiments 
show that zebrafish mrp5 is required for the differentiation of the erythroid lineage 
and for development of normal morphology (Appendix V). The mechanism 
underlying these functions is still unclear; however, it is interesting that morpholino 
knockdown of hrg1 in zebrafish results in comparable anemia and identical 
developmental phenotypes as mrp5 knockdown (40). The similar hrg1 and mrp5 
phenotypes suggest that intercellular transport of heme plays a critical role in early 
development and erythropoiesis in zebrafish. 
We utilized a heme-synthesis deficient yeast strain to show that expression of 
worm, zebrafish, and human MRP5 proteins can alter heme homeostasis in a 
heterologous system (Figures 4.2 and 4.3). Though C. elegans MRP-5 and human 
MRP5 are only 39% identical, they have similar localization and phenotypes in 
hem1∆ yeast. This is again reminiscent of worm and human HRG1 proteins, which 
are only ~20% identical, yet are both able to import heme in these assays using 




the growth assay, we predict that it will show similar localization and phenotypes in 
the CYC1-LacZ and ferric reductase assays. 
It can be argued that the growth assays are an indirect method of showing 
heme transport by MRP5 proteins, as expression of these proteins may be resulting in 
numerous physiological changes in the yeast. We have shown, however, that 
expression of MRP5 can alter two heme-specific reporters located in distinct 
compartments within the cell (Figure 4.4). It is difficult to imagine a mechanism 
whereby heme availability is concomitantly reduced in the cytosol and increased in 
the secretory pathway without invoking direct transport from the former to the latter. 
 It should be noted that, while expression of MRP5 significantly alters both 
heme reporters, the effect is somewhat mild. For example, in the presence of heme, 
expression of human MRP5 in hem1∆ yeast decreases β-galactosidase activity to 50% 
of vector and increase ferric reductase activity two-fold above vector (Figure 4.4A 
and B). Expression of C. elegans MRP-5 reduces β-galactosidase activity to half that 
of vector in the presence of ALA. It is possible, given that the MRP5 transporters are 
being expressed in a heterologous system, that they are missing critical partners 
involved in heme transport. One example of this is heme export by FLVCR1, which 
becomes one hundred times more efficient in the presence of hemopexin (163). 
Another example is the mitochondrial iron import complex comprised of mitoferrin 
and ABCB10. While mitoferrin alone can transport iron into the mitochondrial 
matrix, it requires binding to ABCB10 for increased stability and enhancement of 




We have additionally shown that the defect caused by MRP5 expression can 
be rescued by co-expression with the heme importer, C. elegans HRG-4 (Figure 4.3B 
and C). It is noteworthy that co-expression with HRG-4 does not fully recapitulate the 
growth of yeast expressing HRG-4 alone. This result suggests that, while HRG-4 is 
the strongest heme importer yet identified in these yeast assays (41), heme is exported 
by MRP5 proteins with enough affinity to mitigate the positive effects of HRG-4-








If e’er thy breast with freedom glowed, 
And spurned a tyrant’s chain, 
Let not thy strong oppressive force 
A free-born mouse detain! 
 
Anna Laetitia Barbauld 
“The Mouse’s Petition to Dr. Priestley” 
 
Summary 
 We have previously shown that mrp-5 is a heme exporter in C. elegans and 
that regulation of heme homeostasis is probably a conserved function for MRP5 
proteins in metazoans. Here we show that although mice lacking Mrp5 appear to be 
phenotypically normal, cell culture models show that Mrp5 may play a role in 
mammalian heme transport. Similar to its localization in worms, human MRP5 
localizes to the basolateral membrane in polarized MDCKII cells. In unpolarized 
cells, human MRP5 localizes to the plasma membrane as well as a number of 
endocytic compartments. Mouse embryonic fibroblasts (MEFs) lacking Mrp5 show a 
reduced ability to deliver heme to a hemoprotein reporter targeted to the Golgi, 
indicating that Mrp5 may play a role in delivering heme to the secretory pathway. 
Furthermore, Mrp5, which is expressed in bone marrow-derived macrophages 
(BMDMs), is upregulated in these cells during erythrophagocytosis (EP). In the 




required to respond to EP. These results indicate that MRP5 likely regulates heme 
homeostasis in mammals and possibly plays a role during recycling of senescent red 




 mice do not have hematological defects 
According to the February 2014 release of the annotated mouse genome from 
Ensembl, there are four protein-coding splice isoforms of Mrp5 (Figure 5.1A). The 
two longest transcripts encode identical 1436 amino acid full length Mrp5 proteins, 
but differ in their 3’ untranslated regions. The two shorter transcripts encode shorter 
proteins of 512 and 208 amino acids respectively. These two shorter proteins do not 
contain ABC domains, and are not predicted to be functional transporters. In 
mammals, MRP5 is expressed almost ubiquitously (113, 114, 165) but Mrp5 
knockout mice are viable with no overt phenotypes (130). To knock out Mrp5, de 
Wolf et al targeted exon 15 for replacement with a hygromycin resistance cassette in 
129⁄Ola-derived E14 embryonic stem (ES) cells (Figure 5.1B) (130). F1 offspring 
confirmed to have germline transmission of the mutant Mrp5 allele were backcrossed 
into the FVB genetic background.  




 mice fed 
chow diets [300 parts per million (ppm) iron] showed no difference between the two 
genotypes (Appendix VII, A).  It is important to note that the FVB mouse strain 
inherently has high liver and spleen iron content and is therefore ill-suited for studies 









 fibroblasts.  
(A) In mice, Mrp5 is encoded on the reverse strand of chromosome 16. Four 
alternatively spliced protein-coding variants of Mrp5 are listed on Ensembl and are 
shown here. The two longest transcripts encode identical 1436 amino acid full length 
MRP5 proteins, but differ in their 3’ untranslated regions. The two shorter transcripts 
encode shorter proteins of 512 and 208 amino respectively. These two shorter 
proteins do not contain ABC domains. Protein coding exons are shown in black and 
untranslated regions are shown in white. The red exon is exon 15 targeted for 
deletion; the exons detected by qRT-PCR are shown in blue. (B) Schematic showing 
targeting strategy used to delete Mrp5. Exon 15 was replaced with a hygromycin 
resistance cassette in mouse embryonic stem cells. (C) Immunoblot analysis of Mrp5 





 mice. Membranes were probed with the monoclonal anti-MRP5 antibody, and 
then incubated with HRP-conjugated anti-rat secondary antibody. The MRP5 
















to adequate and low iron diets to perturb heme and iron homeostasis. Mice were 
genotyped and weaned at day 19 postpartum and fed a diet of deionized water and 
food containing either 8 ppm iron (low iron) or 50 ppm iron (adequate iron). After 
eight weeks on the diet, hematological parameters were measured and compared 
between genotypes and diets. All mice fed the low iron diet developed severe anemia, 
as characterized by low hematocrit, low hemoglobin levels and leukocytosis. 




 mice on 
either diet (Appendix VII, B). Additionally, when treated with phenylhydrazine, 
Mrp5
-/-
 mice did not show increased mortality or changes in blood and tissue iron 
levels compared to wild-type brood mates (Mark Fleming, Boston Children’s 
Hospital, personal communication). 
MRP5 regulates heme availability in the secretory pathway 
To determine how loss of Mrp5 affected heme homeostasis in a mammalian 





 embryos. Probing MEF lysates with M5I-10, a monoclonal antibody generated 
against the first 38 amino acids of the mouse Mrp5, revealed a band of the expected 
molecular weight by immunoblotting (Figure 5.1C) (167). The antibody recognized 
endogenous Mrp5 in cell lysates from Mrp5
+/+
 mouse embryonic fibroblasts (MEFs), 
as well as human MRP5 ectopically expressed in Mrp5
-/- 
MEFs (Figure 5.1C, first and 
last lanes). In agreement with previous reports (110), human MRP5 colocalized with 
the basolateral membrane marker, Na
+
-taurochlorate co-transporting polypeptide 




cells (Figure 5.2). We attempted to generate a C-terminal GFP-tagged MRP5 fusion 
protein; however, this construct was mislocalized to the Golgi in polarized cells 
(Appendix VIII). Because of this, and as endogenous Mrp5 was difficult to stain with 
the monoclonal antibody, we instead performed localization studies using ectopically-
expressed untagged human MRP5. In Mrp5
+/+
 MEFs, ectopically expressed human 
MRP5 was found to colocalize not only with the plasma membrane (WGA), but also 
partially with the Golgi (galactosyltransferase) and endosomal recycling organelles 
(Rab4- , Rab5- , Rab9- , and Rab11-positive vesicles) (Figure 5.3). Endogenous 
mouse MRP5 was found to be similarly localized in punctuate intracellular vesicles 
throughout the cytoplasm, with some protein on the cell periphery (Figure 5.4A). 




 MEFs with an 
engineered horseradish peroxidase (HRP) that was confined to the Golgi with a 
targeting sequence (43). Because holo-HRP requires heme as a cofactor, HRP activity 
reflects heme availability in the Golgi compartment (43). When heme-depleted MEFs 
expressing HRP were supplemented with heme in the growth medium, robust HRP 
activity was detected in Mrp5
+/+
 cells but not Mrp5
-/-
 cells; HRP activity was 
significantly suppressed by 65 to 80% in Mrp5
-/-
 cells (Figure 5.4B). Together, these 
results support a model in which mammalian MRP5 is a heme exporter that transports 
heme from the cytosol into the lumen of the secretory pathway, and possibly across 
the plasma membrane. 
Mrp5
-/- 
macrophages have an altered response during erythrophagocytosis 
In order to determine if Mrp5 plays a physiological role in mammalian heme 





Figure 5.2: Localization of human MRP5 in polarized MDCKII cells.  
MDCKII cells stably expressing human MRP5 were transfected with the basolateral 
marker NTCP-GFP or the apical marker Syntaxin3-GFP and grown to confluency on 
transwell filters. Polarization of the monolayer was determined after measuring a 
transient spike in trans-epithelial electrical resistance, which remained above baseline 
level. Cells were fixed and probed with monoclonal anti-MRP5, followed by Alexa 
568-conjugated secondary antibody and imaged using confocal microscopy. A single 









Figure 5.3: Localization of MRP5 in immortalized mouse embryonic fibroblasts.  
Immunolocalization of human MRP5 overexpressed in MEFs by confocal 
microscopy. WGA is used as a plasma membrane (PM) marker, RFP-GalT as a trans-
Golgi (TGN) marker, Rab4YFP marks early endosomes (EE) and the endocytic 
recycling compartment (ERC), Rab5YFP marks EEs, Rab9YFP marks late 










Figure 5.4: MRP5 localizes to the secretory pathway and alters heme levels in 
this compartment.  





 FVB mice.  Cell lysates were resolved on SDS-
PAGE and blotted to nitrocellulose membranes for probing with a monoclonal anti-





 MEFs. Cells were transfected with GolgiHRP and then grown for 24 hr in 
heme-depleted media plus succinyl acetone (HD+SA) for complete heme depletion. 
Indicated amounts of heme were added back and cells were incubated for a further 24 
h. Cell lysates were harvested and analyzed for peroxidase activity, which was 
normalized to peroxidase activity from samples not expressing GolgiHRP and then to 
the protein concentration of each sample. ***P<0.001 for knockout MEFs when 









macrophages (MΦs) of the reticuloendothelial system. MΦs play an essential role in 
heme-iron recycling from dying red blood cells, which are recognized, engulfed, and 
degraded by the MΦs in a process termed erythrophagocytosis (EP). EP is a 
physiological process with an enormous heme transport load, and a process which can 
be studied ex vivo by culturing mouse bone marrow-derived MΦs (BMDMs). 
Consistent with immunohistochemical analysis of MRP5 localization in MEFs, 
MRP5 was found in punctate intracellular vesicles with a small amount of plasma 
membrane staining in BMDMs (Figure 5.5A). 
To determine if Mrp5 gene expression was regulated during EP, BMDMs 
were fed damaged red blood cells, or latex beads as a negative control. Cells were 
harvested at subsequent time points, and RNA extracted from these samples was 
analyzed using quantitative RT-PCR. The Mrp5 transcript was indeed upregulated 4 
hours post-EP (Figure 5.5B); this effect was specific as it was not seen when the 
BMDMs were fed latex beads. Additionally, Western blot analysis showed that 
MRP5 protein levels were also upregulated under EP conditions (Figure 5.5C). 
Feeding BMDMs latex beads did not upregulate MRP5 protein levels, again 
demonstrating the specificity of the MRP5 upregulation (Figure 5.5C, last lane). We 
performed EP on Mrp5
-/-
 BMDMs and no increase in MRP5 signal was detected by 
Western blot, indicating that the increase in MRP5 protein levels was due to 
upregulation of endogenous MRP5, rather MRP5 derived from engulfed red blood 
cells (Figure 5.5D). While Mrp5 is upregulated during EP in BMDMs, 
immunolocalization studies, however, showed that MRP5 does not localize to the 





Figure 5.5: MRP5 is upregulated during erythrophagocytosis in bone marrow-
derived macrophages.  
(A) Immunohistochemistry of endogenous MRP5 in mouse BMDMs. MRP5 staining 
was performed as in Figure 5.4A, using an Alexa 488-conjugated secondary antibody. 
Scale bar, 20 μM. (B) qRT-PCR analysis of Mrp5 transcriptional regulation during 
EP. Relative fold changes (mean ± SEM, n=6) were determined by normalizing the 
CT values to Gapdh and then to CT values of control samples using the ∆∆CT method. 
Control samples were grown in heme depleted media and harvested at time points 
identical to those of the BMDMs fed red blood cells (EP, 10:1 ratio of RBCs: 
BMDMs) or latex beads. (C) Western blot analysis of MRP5 expression in BMDMs 
grown in heme-depleted media (HD) or fed red blood cells (EP) or latex beads. 
Protein was harvested 24 hr after EP. Western blot was performed as in Figure 5.1C. 
Actin is shown as a loading control. (D) Western blot analysis of EP performed on 




 mice shows that MRP5 protein derived 











Figure 5.6: MRP5 does not localize to the phagolysosomal membrane during 
erythrophagocytosis in bone marrow-derived macrophages.  
(A) Immunohistochemistry of ectopically expressed human MRP5 in mouse 
BMDMs. MRP5 staining was performed as in Figure 5.4A, using an Alexa 488-
conjugated secondary antibody. The senescent red blood cells emit autofluorescence, 
as seen in the red channel. Scale bar, 5 μM. (B) Confocal stack image of the cell in 
(A). A single confocal section (xy) is depicted along with composite stacks in side 




To determine if loss of Mrp5 alters the cellular response to EP, we analyzed 




 mice over the course of EP. We measured 
levels of Hmox1 (heme oxygenase 1) and Hrg1 (heme responsive gene 1), which are 
both highly induced in BMDMs in response to EP (43). Hrg1 is involved in heme 
export from the phagolysosome, and Hmox1 is involved in degradation of a portion of 
that heme to release iron (43). When wild-type BMDMs were fed RBCs, both Hmox1 
and Hrg1 were strongly induced at 12 hr post-EP. This post-EP induction was 
attenuated in Mrp5
-/- 
BMDMs, as upregulation of both Hmox1 and Hrg1 was 
significantly repressed in these cells (Figure 5.7A and B). 
Discussion 
 Iron deficiency is the most common nutritional disorder in both developing 
and developed countries (168). According to a World Health Organization report in 
2003, about 60-80% of the world’s population may be iron-deficient (169). While 
intestinal absorption of iron is hindered by the acidic pH of the stomach and the 
presence of metal-chelating compounds found in many foods, dietary heme is a more 
readily absorbed source of nutrient iron (170). Furthermore, in order to meet cellular 
requirements for heme, while concurrently providing protection from heme-
associated toxicity, cellular heme levels are regulated via transport and trafficking 
pathways. Thus heme transport pathways in mammals are important from both a 
nutritional and a cell biological perspective. 
Using genetic analysis in C. elegans and biochemical assays in yeast, we 
identified a conserved family of transporters that regulate organismal heme 









Figure 5.7: MRP5 is required for an appropriate cellular response to 
phagocytosed red blood cells during EP.  




 BMDMs during EP. 
Upregulation of both (A) Hrg1 and (B) Hmox1 is attenuated in knockout cells 
compared to wild-type. Relative fold changes (mean ± SEM, n=6) were determined 
by normalizing the CT values to Gapdh and then to CT values of control samples 
using the ∆∆CT method. Control samples were grown in heme depleted media and 
harvested at time points identical to those of the BMDMs fed red blood cells (EP, 
10:1 ratio of RBCs: BMDMs). BMDMs fed latex beads are shown as a negative 
control. ** P<0.01, *** P<0.001 compared to wild-type cells under identical 




number of experiments using both mice and cell culture models. While Mrp5
-/- 
mice 
have no apparent phenotype, we were able to uncover a number of defects in Mrp5
-/-
 
cell types. In immortalized MEFs, Mrp5 localized to the plasma membrane and 
intracellular compartments, including endocytic recycling vesicles. Mirroring our 
results from assays in hem1Δ yeast, Mrp5
-/-
 MEFs have a decreased ability to deliver 
heme to a heme reporter localized to the Golgi apparatus. Additionally, BMDMs 
derived from Mrp5
-/- 
mice have a decreased ability to transcriptionally upregulate 
machinery necessary for erythrophagocytosis.  
In worms, yeast, and mammalian cells, MRP5 localizes to both the plasma 
membrane and intracellular vesicles.  The cell surface localization of MRP5 could be 
reconciled with the well-studied function of ABCC transporters to efflux substrates 
into the extracellular milieu, consistent with the expected role of exporting heme from 
the C. elegans intestine into the worm’s circulatory system. However, MRP5 is also 
found in the secretory pathway as part of the endocytic recycling compartment. While 
we do not show that MRP5 has heme export activity by direct biochemical assays or 
that it can deliver heme to an endogenously-expressed mammalian hemoprotein, our 
genetic and cell biological results in yeast and MEFs support a model in which heme 
transported into the secretory pathway by MRP5 is incorporated into luminal 
hemoproteins (Figure 5.8). 
 Given the severe phenotypes associated with mrp-5 deficiency in worms and 
zebrafish, why do Mrp5 null mice not exhibit any overt hematological phenotypes? 
Clearly, worm and human MRP5 have similar phenotypes in yeast. One plausible 









Figure 5.8: Proposed model for MRP5 function in mammalian cells.  
Based on results from genetic, biochemical, and localization studies in yeast and cell 
culture models, MRP5 can localize to the plasma membrane for heme export as well 




heme export, while MRP5 performs a more specialized role (35, 36, 171). It is 
notable that worms in which each of the five FLVCR homologs were depleted 
exhibited no heme-dependent phenotypes signifying that, at least in C. elegans, MRP-
5 plays a definitive and essential role in heme homeostasis.  
A second explanation is the influence of the FVB genetic background of the 
Mrp5 mutant mouse (130). Inherently, the FVB strain has high liver and spleen iron 
content and therefore ill-suited for studies of systemic iron homeostasis.  This is in 
contrast to the C57BL/6 strain which has a much lower liver and spleen iron content 
and, therefore, presents a mouse model that is more sensitive to perturbation in iron 
metabolism (166). For example, mutations in the iron transporter DMT1 are viable in 
certain mouse strains, but become lethal when backcrossed into the C57BL/6 
background (Mark Fleming, Boston Children’s Hospital, personal communication). 




 mice was performed in mice that had been 
backcrossed to C57BL/6 five times, it is possible that residual background from the 
original FVB lineage is masking an iron-dependent phenotype.  
Lastly, in vivo compensatory pathways may exist to overcome heme or iron 
metabolism defects in Mrp5
-/-
 mice. It is noteworthy that in humans and other 
placental mammals, MRP5/ABCC5 has two recently described paralogs – 
MRP8/ABCC11 and MRP9/ABCC12; mice and zebrafish genomes contain only 
MRP9/ABCC12 (155, 172, 173). Although it has been reported that MRP9/ABCC12 
also localizes to the secretory pathway in unpolarized mammalian cells (174), the 




Our immunofluorescence studies indicated that, consistent with previous 
reports, MRP5 localizes to the plasma membrane and endocytic compartments in 
unpolarized cells. The endosomal trafficking of MRP5 could be mediated by an 
acidic-dileucine based sorting signal located in the cytoplasmic carboxy termini of 
vertebrate MRP-5 proteins (175). It is noteworthy that ATP7A, a copper-transporting 
P-type ATPase, pumps copper into the secretory compartment for metallation of 
essential cuproproteins in the Golgi, as well as export copper across the plasma 
membrane to regulate body copper stores (176). Conceivably, MRP5 may perform a 
similar dual function as a heme transporter. 
The mechanism by which loss of Mrp5 interferes with the 
erythrophagocytosis response in BMDMs remains unclear. Repression of Hrg1 and 
Hmox1 would seem to indicate that less heme is being transported into the cytosol of 
these cells; that is, that Mrp5 is involved in the mobilization of heme from the 
phagolysosome. However, there are a number of reasons to indicate that this is not the 
case. First, localization studies have shown the Mrp5 is not localized to the 
phagolysomal membrane during EP. Second, with few exceptions, the vast majority 
of eukaryotic ABC transporters have been shown to be exporters. Every previous 
result in C. elegans, yeast, and MEFs has indicated that MRP5 proteins are indeed 
exporters, moving heme from cytosolic compartments to extracellular or luminal 
compartments. Transporting heme from the lumen of the phagolysosome into the 
cytosol would involve transport in the opposite direction.  
One explanation for our results in BMDMs is that loss of Mrp5 results in 




the cells under a microscope does not reveal any obvious difference in the amount of 
senescent red cells taken up by Mrp5
-/-
 BMDMs. Another more provocative 
explanation is that macrophages sense and respond to the red cell-derived heme influx 
via the secretory pathway. Sterol response element binding protein (SREBP) is 
located in the secretory pathway but can signal cholesterol status to the nucleus via a 
cleaved transcription factor domain (177). It is possible that response proteins sense 
heme status in this same compartment and are part of the macrophage response 
during erythrophagocytosis. In the absence of a transporter such as Mrp5 bringing 




Chapter 6: Discussion 
 
This tree has two million and seventy-five thousand leaves. Perhaps I missed a leaf or 
two but I do feel triumphant at having persisted in counting by hand branch by 
branch and marked down on paper with pencil each total. Adding them up was a 
pleasure I could understand; I did something on my own that was not dependent on 
others, and to count leaves is not less meaningful than to count the stars, as 
astronomers are always doing. They want the facts to be sure they have them all. It 
would help them to know whether the world is finite. I discovered one tree that is 
finite. I must try counting the hairs on my head, and you too. We could swap 
information. 
 




For almost two decades, MRP5 has been studied as an exporter of cancer 
drugs, organic anions and nucleoside monophosphates, although none of these studies 
provided direct genetic evidence for a physiological role for MRP5 in growth and 
development (105, 110, 114). The goal of this project was to delineate the role that 
mrp-5 plays in C. elegans heme homeostasis, and to determine if this protein is a 
conserved heme transporter. The major findings of these studies are outlined below. 
1) Using microarray analysis and genetic screens, we identified mrp-5 as 
a regulator of heme homeostasis and a putative heme transporter. MRP-5 is a 
membrane-bound ABC transporter that is upregulated in C. elegans during 
heme deficiency. Depletion of mrp-5 causes upregulation of a heme 




from toxicity associated with GaPPIX. These results indicated that mrp-5 
likely regulates heme entry into the worm. 
2) Knockdown of seven mrp paralogs and five putative homologs of the 
heme exporter, Flvcr1, did not result in heme-dependent phenotypes in 
IQ6011. While any of these genes may play a more subtle role in regulating 
heme homeostasis in C. elegans, mrp-5 appears to be the sole member of 
these genes that serves as a master regulator of heme entry into the worm. 
While Flvcr1 clearly plays a role in mammalian heme homeostasis, as seen 
via the anemia and lethality of Flvcr1
-/-
 mice, it is apparent that mrp-5 is the 
definitive heme homeostasis regulator in C. elegans. 
3) Worms expressing mrp-5 transcriptional and translational fusions 
revealed that mrp-5 is expressed in multiple tissues, but that this protein is 
found mainly on the basolateral membrane of the intestine. Depletion of mrp-
5 specifically in the intestine results in F1 lethality, and accumulation of 
ZnMP in the intestine, with a concomitant increase in extra-intestinal heme 
depletion signals. As most eukaryotic ABC transporters function as exporters, 
we concluded that mrp-5 encodes an intestinal heme exporter. This conclusion 
is supported by biochemical assays in yeast, showing that mrp-5 can modulate 
heme transport when expressed in a heterologous system. 
4) Both RNAi-depletion and genetic deletion of mrp-5 results in severe 
embryonic lethality and developmental arrest in C. elegans, indicating that an 
alternate pathway is unable to compensate for loss of heme export by mrp-5. 




hrg-4, is not highly regulated by heme levels in the diet, we conclude that 
mrp-5 is part of an essential, basal heme transport pathway. As hrg-1 through 
hrg-4 are not expressed at higher heme concentrations, and only exhibit mild 
heme-dependent phenotypes under severe heme limitation conditions, we 
conclude that these genes are part of an emergency network upregulated in 
response to heme starvation. 
5) An HRG-3-dependent pathway for heme export from the intestine has 
already been delineated (77), but as previously noted, this pathway is unable 
to compensate for loss of mrp-5. While loss of mrp-5 appears to downregulate 
hrg-3 expression, this is not the reason for the inability of hrg-3 to rescue 
mrp-5(RNAi), as ectopic expression of hrg-3 also failed to rescue the defect. It 
is possible that MRP-5 is required for heme delivery to HRG-3 during its 
maturation and exocytosis, as we showed that MRP5 delivers heme to the 
secretory pathway in assays in yeast and mammalian cell culture models.  
6) Knockdown of mrp-5 presumably results in heme buildup in the 
intestine, in parallel with depletion in extraintestinal tissues. This is reflected 
in the upregulation of the extraintestinal hrg-2 promoter, and downregulation 
of the hrg-3 promoter. Interestingly, the intestinal hrg-1 promoter is 
upregulated by depletion of mrp-5. While it is possible that mrp-5(RNAi) 
partitions intestinal heme to compartment where it cannot be detected by the 
hrg-1 promoter, a more intriguing possibility is that extraintestinal heme 
deprivation signals are capable of upregulating the hrg-1 promoter. This 




release of stored intestinal heme in the event it was required by extraintestinal 
tissues. 
7) Vertebrate MRP5 is 39% identical to C. elegans MRP-5 and zebrafish 
Mrp5 is ~74% identical to mammalian MRP5. Morpholino knockdown of 
mrp5 resulted in severe anemia and developmental defects, which were 
specifically rescued by co-injection with zebrafish mrp5. Loss of the 
erythropoietic-specific transcription factor in mrp5
MO
 fish indicated that mrp5 
is required for differentiation of red blood cells. While the mechanism 
whereby loss of mrp5 results in anemia remains unknown, these results 
indicate that MRP5 likely plays a role in regulating heme homeostasis. It is of 
note that knockdown of the heme importer hrg1 results in similar defects in 
zebrafish – indicating that intra- and possibly inter- cellular heme transport is 
required for development and erythropoiesis. 
8) Worm and human MRP5 localized to intracellular membranes when 
ectopically expressed in Saccharomyces cerevisiae. When expressed in a 
heme-synthesis deficient yeast strain, both proteins result in heme-dependent 
inhibition of growth, decreased heme availability in the cytoplasm and 
increased heme levels in the secretory pathway. We conclude that heme efflux 
by MRP5 transporters is likely conserved in metazoans. 
9) Mice lacking Mrp5 appear to be phenotypically normal. Even after 
being backcrossed five times into the iron-deficient C56BL/6 mouse strain, 
and even after induction of iron-deficiency anemia, their hematological 




were indistinguishable from wild-type animals. Possible reasons for this 
include compensation by another heme transporter or the Mrp5 paralog, 
Mrp9/Abcc12; residual effects of the FVB genetic background; or that Mrp5 
plays a more specialized role in heme homeostasis in mammals. 
10) When ectopically expressed in unpolarized fibroblast cells, human 
MRP5 localizes to the plasma membrane and various endocytic and recycling 
vesicles. In polarized MDCKII cells, MRP5 localized to the basolateral 
membrane. Thus, in agreement with our previous studies of HRG1 and HRG4, 
MRP5 has a similar expression pattern in C. elegans, yeast, and mammalian 
cells. 
11) In a cell culture model, loss of Mrp5 resulted in decreased activity of a 
genetically-encoded heme reporter localized to the Golgi apparatus. We 
conclude that Mrp5 may transport heme into the secretory compartment, a 
heme transport pathway that has yet to be elucidated. 
12) Mrp5 is upregulated at the transcript and protein levels in bone 
marrow-derived macrophages undergoing erythrophagocytosis. Similar to its 
expression in fibroblasts, Mrp5 localizes to the plasma membrane and 
intracellular compartments in these cells; however, unlike Hrg1, Mrp5 is not 
enriched on the phagolysosomal membrane. Analysis of BMDMs lacking 
Mrp5 revealed that genes normally upregulated during EP are significantly 
attenuated. The mechanism behind this defect remains unknown, however it is 






Structure/Function Analysis of MRP5 Proteins 
A mechanistic understanding of how MRP5 proteins transport heme has yet to 
be elucidated. In general, the mechanisms of substrate binding by multidrug resistant 
ABC transporters remain poorly understood (178, 179). Many ABC proteins are able 
to transport a variety of drugs/substrates which have minimal structural similarities. It 
is unlikely that highly specific interactions between ABC transporter substrates and 
protein side chains exist for every single compound capable of being transported by 
this class of protein. We analyzed whether functional domains or motifs exist for 
heme binding in MRP-5. We found no regions of similarity between MRP5 and either 
HRG-1, HRG-4, PUG1, or even FLVCR. There are also no canonical heme binding 
motifs (CP, CxxCR, CxxCK, or CxxCM) in MRP5. Despite this, we have identified a 
number of possible heme-binding residues that are conserved in MRP5 proteins, but 
not in other ABCC family members. These include: 
 tyrosines found in the second transmembrane segment (TM2) and nearby 
cytosolic loop (between TM2 and TM3) in human mouse, zebrafish, and worm MRP5 
that are not conserved in any other worm or human ABCC/MRP protein 
 tyrosine and cysteine residues in the cytosolic loop between TM4 and TM5 
that are conserved in human, mouse, fish, and worm MRP5 and related proteins 
(ABCC11 and MRP9/ABCC12) 
 a histidine in the cytosolic loop between TM10 and TM11 that is found in all 
MRP5 and related proteins in humans, mice, fish, and worms, but is a highly 




We propose to generate worm and human MRP5 proteins containing mutants 
in these residues and other conserved putative heme-binding residues. We will also 
generate mutants containing missense mutations in the conserved ABC transporter 
motifs (Walker A and signature motifs) in both the first and second NBDs of MRP5 
as a positive control for abrogation of heme transport activity. Additionally, we found 
a single nucleotide polymorphism (SNP) in the human SNP database (dbSNP 
identification number: rs1053351) which is predicted to result in a premature stop 
codon before the second NBD (180, 181). We will test this mutation as well.  
Similar to the structure/function analysis of HRG1 proteins, these mutants will 
first be tested in for modulation of growth and heme reporters in the hem1∆ yeast 
strain. We will also determine if expression of human MRP5 is capable of rescuing 
mrp-5(ok2067) worms. Any mutations found to affect heme transport by MRP5 in 
yeast will be further tested for their ability to rescue mrp-5(ok2067) in C. elegans. 
MRP5 proteins from other species can be analyzed for heme transport in the 
various models used in this work. We can test MRP5 proteins from zebrafish or 
mouse for their ability to rescue mrp-5(ok2067). While zebrafish Mrp5 has been 
shown to regulate growth of hem1∆ yeast, it is yet to be determined if it can modulate 
the activity of the CYC1-LacZ reporter gene or ferric reductase in the 
hem1∆fre1∆fre2∆MET3-FRE1 yeast strain. We can also test the ability of wild-type 
and mutant MRP5 from different species to rescue the loss of Golgi-HRP activity in 
an Mrp5
-/-
 background (although co-expression of proteins with the HRP construct in 




Interacting Partners and Other Heme Trafficking Mechanisms 
 The strong heme-dependent lethality phenotype of mrp-5(ok2067) worms 
makes them a powerful tool for uncovering additional mechanisms of heme transport 
in C. elegans. Simon Beardsley, a graduate student in our laboratory, has performed a 
mutagenic screen in this strain, looking for by-pass suppressor mutations that enable 
these worms to be propagated at low heme concentrations. He has identified over 30 
mutants that suppress the lethality associated with mrp-5(ok2067) allele and is 
currently analyzing growth of these mutants in the presence of GaPPIX and 
localization of ingested ZnMP in these worms. Consistent with their restored ability 
to grow at low heme, preliminary analysis shows that all mutants suppress the mrp-
5(ok2067)-associated rescue in the presence of GaPPIX. Interestingly, these 
suppressors appear to process ZnMP in different ways. For example, certain mutants 
show increased intestinal ZnMP compared to mrp-5(ok2067) worms, while others 
have intestinal ZnMP returned to wild-type levels. These results imply distinct 
mechanisms for rescue of the mrp-5 deletion – either increased heme import to the 
intestine, or increased heme export from the intestine. It is likely that at least some of 
these mutations occur in genes involved in heme homeostasis. Given that MRP5 is 
conserved in metazoans, it is possible that mechanisms that rescue loss of mrp-5 will 
be conserved as well. 
 Additionally, a number of members of our lab have performed 
immunoprecipitation experiments on proteins of interest (i.e. HRG1), followed by 
multidimensional protein identification technology (MudPIT) analysis in 




experiments, protein partners that are bound to the protein of interest are co-
immunoprecipitated; mass spectrometry techniques are then used to identify 
interacting partners. This could be performed on MRP5 expressed in C. elegans or a 
mammalian system, and would act in parallel with the genetic screen to identify novel 
in vivo partners of MRP5. 
Zebrafish Mutant Analysis 
 Jianbing Zhang, a graduate student in our laboratory has done extensive work 
characterizing phenotypes associated with morpholino knockdown of mrp5 in 
zebrafish. He is currently using CRISPR technology to generate a null allele of mrp5 
in zebrafish. He has genotyped founder fish containing mrp5 mutations, and 
intriguingly, offspring that are putatively mrp-5-null appear unhealthy. Future work 
with the mrp5 morpholino and mutant fish will determine the role that mrp5 plays in 
maternal-fetal nutrient heme transfer, embryonic development, and differentiation of 
erythroid cells in these animals. 
Heme Transport Assays 
 A major caveat of these studies is that we have not shown direct evidence of 
heme transport by MRP5. In most of biological models described in this work, MRP5 
localizes to subcellular compartments. Changes in heme concentrations on a 
subcellular level are inherently difficult to demonstrate directly, as one would for a 
plasma membrane-localized transporter. One promising model is polarized MDCKII 
cells. First, in these cells, MRP5 traffics to the basolateral membrane, which thus lack 




transport assays, MRP5 would be present in its native milieu, including any 
interacting factors required for optimal transport. Directional transport of heme could 
be shown by adding radiolabelled heme to the media facing the apical surface of these 
cells, and showing differences in heme efflux from the basolateral membrane of cells 
overexpressing MRP5 or those treated with siRNA against MRP5. Dr. Tamika 
Samuel, a research assistant professor in our laboratory, is currently establishing 
assays to measure radiolabelled heme uptake in Leishmania and yeast. These assays 
could theoretically be modified to test heme efflux by MRP5. 
Analysis of Mrp5 Knockout Mice 
 It was surprising to learn that Mrp5
-/-
 mice have no overt hematological 
defects, even when raised on an iron-depleted diet. We hypothesize that, unlike 
Flvcr1, Mrp5 might play a more specialized role regulating heme homeostasis in 
these animals. Analysis of Mrp5
-/-
 fibroblasts revealed defects in heme transport into 
the Golgi apparatus, as well as an altered cellular response to EP in bone marrow-
derived macrophages, indicating, that at least in certain contexts, Mrp5 is required for 
normal heme trafficking. 
 Given the results of our yeast and Golgi-HRP assays, we identified 
hemoproteins found in the secretory pathway, whose activity could be modulated in 
the presence or absence of Mrp5. These include the prostaglandin-synthesizing 
cyclooxygenases (COX1 and COX2) and the neutrophil-specific antimicrobial 
protein, myeloperoxidase (MPO). We are currently collaborating with Dr. Sandeep 
Prabhu at The Pennsylvania State University to measure prostaglandin levels and 
MPO activity in wild-type and Mrp5
-/-




COX1 nor MPO has obvious phenotypes in mice (184, 185). COX2-deficient mice 
exhibit renal abnormalities and early mortality (185). 
Significance 
In most animals, heme is synthesized via a highly conserved eight-step 
pathway shared between the mitochondria and the cytosol (186). The pathway 
concludes in the mitochondrial matrix, where iron is catalytically inserted into a 
protoporphyrin IX ring to produce heme. Heme must be exported from the 
mitochondria for incorporation into hemoproteins located in various subcellular 
compartments (187). However, the process of trafficking unescorted heme to 
subcellular compartments exposes the cell to heme-associated toxicity. Thus heme 
levels within cells and within subcellular compartments must be highly regulated by a 
network of transporters and chaperones. 
In this study, we show that mrp-5 encodes an intestinal heme exporter that 
plays a vital role in maintaining heme homeostasis in the worm. Loss of maternal and 
larval mrp-5 result in embryonic lethality and growth arrest, respectively, and both of 
these phenotypes can be rescued with dietary heme. Loss of mrp-5 protects against 
lethality associated with ingestion of a toxic heme analog, and results in a number of 
heme deficiency signals that persist even as worms are fed greater than physiological 
amounts of heme. Data from functional yeast assays, combined with evidence that 
mrp-5 is expressed in the intestine and localizes to the basolateral membrane, reveal 





Additionally, we show that heme transport by MRP5 is conserved among 
metazoans. Knockdown of Mrp5 in zebrafish embryos results in developmental 
defects and decreased blood formation. Loss of Mrp5 in mammalian cells leads to 
decreased heme transport into the secretory pathway as measured by activity of a 
Golgi-targeted heme-dependent enzyme. Furthermore, macrophages from mice 
lacking Mrp5 are unable to activate a number of cellular responses when undergoing 
erythrophagocytosis. Altogether, our results implicate MRP-5 as a key heme 
transporter in C. elegans, and point to an evolutionarily conserved role for MRP-5 in 
regulating heme homeostasis. 
We envisage that cellular heme levels in C. elegans, and plausibly vertebrates, 
are not solely regulated by internal heme content, but also by distally located proteins 
which signal systemic heme requirements to an inter-tissue heme trafficking network. 
This prediction is supported by our findings that depletion of either a heme exporter 
(mrp-5) or a heme importer (hrg-1) produces similar, overlapping phenotypes in 
worms and zebrafish i.e. that mobilization of heme in and out of tissues is as 
important as endogenous heme synthesis (40, 41, 43). Although both heme importers 
and exporters are obviously essential for survival of a heme auxotroph, these proteins 
also play an important role in vertebrates as demonstrated by developmental and 
blood defects in zebrafish. 
The severity of phenotypes associated with loss of heme synthesis indicates 
that intracellular heme trafficking pathways are not the primary modes to support the 
heme requirements of animals. The generation of (a) tissue-specific heme synthesis 




new modalities of live imaging of heme using label-free microscopy at the tissue and 
subcellular level would be greatly beneficial in determining the capacity for inter- and 
intra-tissue heme transport. Ultimately, these pathways (including MRP5-mediated 
heme transport into the secretory pathway or across the plasma membrane) may be 
relevant under specific conditions of aberrant iron or RBC homeostasis, or during 
pathogenesis.  
While heme transport pathways are of interest from a cell biological 
perspective, they are also of great interest to human health. Iron deficiency is the most 
common nutritional disorder in developing and developed countries (168). About 60-
80% of the world’s population may be iron deficient according to a World Health 
Organization report published in 2003 (169). Dietary heme is more readily absorbed 
that dietary iron, as a number of factors cause iron to be less bioavailable in the 
human gut (170). Knowledge of heme trafficking will aid in understanding and 
improving the efficiency of iron absorption and transport through the body. This 
understanding will additionally provide insight into role of heme in human disease, as 
many pathogens rely on host-derived iron for their virulence (188-190). Worm-
specific heme transport pathways will be valuable targets for anthelminthics, because, 
like C. elegans, most parasitic nematodes do not synthesize heme but are dependent 
on host heme. These helminths, which are developing resistance to current drugs, 
present an enormous global threat to human health and agriculture and exacerbate 
global iron deficiency. Thus, characterization of worm and mammalian heme 
transporters will both illuminate heme transport pathways, and identify therapeutic 










Background Transgene Source 
IQ5051 unc-119 (ed3) III 
P
mrp-5
::GFP::unc-54 3’ UTR; 
unc-119 rescue 
This study 
IQ5052 unc-119 (ed3) III 
P
mrp-5
::GFP::mrp-5 3’ UTR; 
unc-119 rescue 
This study 




3’ UTR; unc-119 rescue 
This study 










IQ5951 mrp-5 (ok2067) X - This study 
IQ5051 unc-119 (ed3) III 
P
mrp-5






::GFP::unc-54 3’ UTR; 
rol-6 marker 
(40) 




3’ UTR; unc-119 rescue 
(141) 
IQ8031 unc-119 (ed3) III 
P
hrg-3
::GFP::hrg-3 3’ UTR; 
unc-119 rescue 
(77) 




3’ UTR; unc-119 rescue 
(77) 




3’ UTR; unc-119 rescue 
(77) 
VP303 rde-1(ne213) V Pnhx-2::rde-1; rol-6 marker CGC 

















Oligonucleotide primers used in this study 
 
Purpose Name Sequence 
mrp-5(ok2067) 
Genotyping 
5’ Flank (A) GATGGCTCAAGAAAGGACACG 
 5’ Internal (B) TGGTAGCTCCATGAATGACGG 
 3’ Internal (C) GGTATTTGTTTCATGCTTCCGTGC 
 3’ Flank (D) AGCATGACTGTCAAAAGTGCG 
C. elegans qRT-
PCR 
5’ qgpd-2 TGCTCACGAGGGAGACTAC 
 3’ qgpd-2 CGGTGGACTCAACGACATAG 
 5’ qhrg-1 AATGGCAGGATGGTCAGAAAC 
 3’ qhrg-1 CGATGAATGAAAGGAACGATACG 
 5’ qmrp-5 CTCTTCTCCTTTGTCACCTACTC 
 3’ qmrp-5 TCTCATCTTCCCATAACACTTCC 
Mouse Mrp5 
Genotyping 
5’ Mrp5 Genotype CTAGAGTCTAATCCGTATTGG 









Mouse qRT-PCR 5’ mGapdh CTCCACTCACGGCAAATTCAAC 
 3’ mGapdh GTAGACTCCACGACATACTCAGC 
 5’ mMrp5 GGCTGGACCTCATCAGCATT 
 3’ mMrp5 GATGCCAGTCTGACGGTGAA 
 5’ mHrg1 CTTCGTGGGTGCTCTCTTCTC 
 3’ mHrg1 GACTCTGATGCTGGGTGATGG 
 5’ mHmox1 TGGTGCAAGAT ACTGCCCCT 







The mrp-5(ok2067) allele is an in-frame deletion that results in a dysfunctional 
protein. 
 
(A) Sequencing chromatogram showing deletion boundaries (arrows) and deleted 
region (dotted line), respectively, in the wild-type (top) and mrp-5(ok2067) (bottom) 
transcripts after RT-PCR. (B) RNAi of mrp-5 in mrp-5(ok2067) mutant worms causes 
no added embryonic lethal phenotype. Mutant worms were grown at 500 μM heme, 
and their synchronized L1 progeny were grown on vector or mrp-5(RNAi) plates and 
their subsequent progeny were scored for hatching. Error bars represent standard error 
of the mean; ns, not significant (two-way ANOVA, Bonferroni post-test). (C) RNAi 
of FLVCR homologs in mrp-5(ok2067) background results in no added heme-specific 
phenotypes. Error bars indicate standard error of the mean. ***P<0.001 when 
compared to vector control under identical conditions (two-way ANOVA, Bonferroni 
post-test). 
 










In situ hybridization reveals tissue specific expression of mrp5.  
 
Zebrafish mrp5 expression by whole mount in situ hybridization using anti-sense 
probe, at indicated developmental stages. Anterior is to the left. Sense probe image is 
shown to indicate background staining. 
 










mrp5 is required for zebrafish erythropoiesis.  
 
(A) Lateral view of zebrafish mrp5 expression by whole mount in situ hybridization 
using anti-sense probe, 4 days post-fertilization. Anterior is to the left. Sense probe 
image is shown to indicate background staining. B, brain, N, neural tube. (B) 
Knockdown of zebrafish mrp5 using morpholinos (MO
mrp5
) results in severe anemia, 
as indicated by reduced staining of o-dianisidine-positive red cells, as indicated by 
black arrowheads. (C) Transgenic embryos expressing GFP from the globin locus 
control region (LCR-GFP) were injected with control MO or MO
mrp5
. LEFT: On day 
2 post-fertilization, percent GFP-positive RBCs was analyzed by FACS. X and Y 
axes measure GFP and forward scatter, respectively; boxed area indicates gate for 
RBCs. RIGHT: Quantification of morphants shown at left. For MO
mrp5
 injection, n=4. 
**P<0.01 for MO
mrp5
 morphants compared to control morphants under identical 
conditions. (One-way ANOVA, Bonferroni post-test.) (D) Lateral view of zebrafish 
gata1 expression in wild type, control MO, and MO
mrp5
 morphants by whole mount in 
situ hybridization using anti-sense probe, 24 hpf. Anterior is to the left. (E) 
Quantification of anemia rescue in zebrafish co-injected with mrp5 cRNA. 
***P<0.001 for MO
mrp5
 morphants compared to control morphants under identical 
conditions, n=4. **P<0.01 for mrp5 morphants co-injected with rescue cRNA when 
compared to mrp5 morphants with no rescue cRNA under identical conditions, n=3 
(One-way ANOVA, Bonferroni post-test.) 
 










Zebrafish Mrp5 inhibits heme-dependent growth in hem1∆ yeast.  
The hem1∆ yeast strain was transformed with empty vector, CeHRG-4, CeHRG-1, or 
MRP5, grown overnight without added heme or ALA and spotted on plates 
supplemented with 0.25 or 10 μM heme. Plates were incubated at 30°C for 72 h 
before imaging. 
 











Appendix VII. Mrp5-/- mice are hematologically normal 
Hematological parameters of (A) Mrp5 wild-type and knockout mice on chow diet 
[wild-type mice, n=10; knockout mice, n=12] and (B) Mrp5 wild-type and knockout 
mice weaned onto adequate or low iron diets [wild-type mice on adequate iron, n=4; 
wild-type mice on low iron, n=5; knockout mice on adequate iron, n=6; knockout 
mice on low iron, n = 4]. No significant difference was seen between genotypes on 
chow, adequate iron, or low iron diets. Samples were acquired by retro-orbital 
bleeding and parameters were analyzed using a ProCyte Dx hematology analyzer 











A C-terminal MRP5-GFP fusion is mislocalized to the Golgi apparatus. 
 
GFP-tagged MRP5 mislocalizes to the Golgi in polarized MDCKII cells. MDCKII 
cells stably expressing human MRP5 were transfected with the basolateral marker 
NTCP-GFP or the Golgi marker GalT-mCherry and grown to confluency on transwell 
filters. Polarization of the monolayer was determined by measuring a spike in trans-
epithelial electrical resistance. Cells were fixed, stained for MRP5 as necessary, and 
imaged using confocal microscopy. A single confocal section (xy) is depicted along 
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